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Abstract 
Malaria is an infectious disease caused by Plasmodium parasites, transmitted by the female 
Anopheles mosquito. Malaria can cause mild symptoms as well as more severe complications 
which may lead to death. Annually, there are half a million deaths worldwide with millions 
more newly infected with malaria. Although antimalarials exist, due to the prevalence of drug 
resistance, novel, more effective treatments are needed to combat malaria by aiding the host 
immune response. One of the earliest signs of a malarial infection is a decrease in the 
concentration of platelets in the blood of infected individuals - clinically referred to as 
thrombocytopenia. Platelets have been shown to play a protective role during a malaria 
infection by targeting the parasite vacuole via platelet factor 4 (PF4). PF4 is only released 
from activated platelets upon contact with infected red blood cells (iRBCs), and not 
uninfected red blood cells (uRBCs). The molecules responsible for platelet activation and 
subsequent release of PF4 from iRBCs were to be determined in this thesis. Platelet activation 
via infected lysate from trophozoite stage parasites was originally observed but not 
consistent. Purified trophozoites were unable to activate platelets hence the molecule of 
interest was unable to be determined.   
The second part of this thesis was to measure the contribution of platelets binding to RBCs 
in thrombocytopenia. It has been previously shown that platelets bind preferentially to iRBCs 
compared with uRBCs. No definite mechanism of thrombocytopenia has been elucidated to 
date, although a number, such as splenic pooling and endothelial activation, have been 
thought to play a role. In this thesis, it was hypothesised that platelet binding and subsequent 
clearance may be responsible for malaria-induced thrombocytopenia. Before the onset of 
thrombocytopenia, preferential binding of platelets to iRBCs was observed and although 
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platelets were cleared more quickly in infected mice, the contribution of platelet bound RBCs 
was unable to be definitely identified. 
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Chapter 1 Introduction 
 
1.1 Malaria 
Malaria is caused by protozoan parasites belonging to the genus Plasmodium and is one of 
the deadliest diseases affecting the human population [1]. Of the five species of human 
malarial parasites (Plasmodium falciparum, P. vivax, P. malariae, P. knowlesi and P. ovale), 
[2], P. falciparum is the predominant species threatening the human population in endemic 
areas. The 2016 World Health Organization (WHO) report stated 212 million new cases and 
429,000 deaths due to malaria [3] occurred in 2015, with the majority of the cases and deaths  
recorded in the Sub-Saharan African region. This was followed by South-East Asia and the 
Eastern Mediterranean region [3]. To reduce and prevent malaria transmission in endemic 
areas, vector control has been implemented either by implementation of insecticide-treated 
mosquito nets, or indoor residual spraying [4]. In Sub-Saharan Africa, insecticide-treated 
mosquito nets were heavily used with an estimated 53% of the population at risk of malaria 
sleeping under a net in 2015 compared to 30% in 2010 [3]. Furthermore, 106 million people 
world-wide were protected from malaria transmission by indoor residual spraying including 
49 million people in Africa, with  the proportion of the population at risk declining from a 
peak of 5.7% globally in 2010 to 3.1% in 2015 [3]. 
Figure 1.1 shows the current global malaria landscape by country where more than half the 
world’s countries have eliminated malaria from their borders [5]. 
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Figure 1.1: Worldwide distribution of malaria. Current landscape of malaria showing 
more than half the world’s countries have eliminated malaria. Regions including Sub-
Saharan Africa and Asia are clearly still at the lowest end of the spectrum, though highlighted 
in pink as "controlling malaria". Figure taken from [5, 6]. 
 
1.2 History of Malaria 
Malaria infections have been recorded for thousands of years, with texts from ancient 
civilizations of India, China and Greece alluding to fevers which identify as malaria. The 
writings of Hippocrates described the reoccurrence of malaria and the association between 
an enlarged spleen and a patient’s residence in a low-lying, marshy area [7]. Malaria was 
coined from the medieval Italian words ‘mala’ and ‘aria’ meaning ‘bad air’ [8]. It was not 
until 1880 where Alphonse Laveran performed necropsies on malaria victims and found, in 
the majority of cases, pigmented bodies which were moveable were found in the blood. He 
concluded the rapid movement must be parasites and that these must be the cause of malaria 
which he called Oscilliaria malariae which was later reclassified to Plasmodium [9].  
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1.3 Life cycle of Malaria  
The life-cycle of the malaria parasite begins when the female Anopheles mosquito harboring 
the parasite in its salivary gland, takes a blood meal from a human host. Subsequent to the 
mosquito bite, the parasite, in the form of sporozoites, travels to the liver via the bloodstream 
where they invade hepatocytes and proliferate asexually. From here they develop into 
schizonts, and release from hepatocytes as merozoites [10]. Merozoites re-enter the blood 
stream and invade red blood cells (RBCs), after which the intra-erythrocytic parasite mature 
and asexually reproduces into schizonts, eventually rupturing the RBC and releasing newly 
formed merozoites to invade new RBCs. The sexual stage occurs when some merozoites 
mature into gametocytes. Following ingestion by mosquitoes during a blood meal, an 
individual gametocyte may form one female macrogamete or up to eight male microgametes 
[11]. In the mosquito midgut, gamete fusion produces a zygote that develops into a motile 
ookinete. At this stage, there is an opportunity for recombination between genetically distinct 
parasite isolates, or outcrossing to create genetic diversity [12]. The ookinetes subsequently 
penetrate the midgut of the wall and form oocysts [11]. Over time, the oocysts enlarge and 
burst to release sporozoites that migrate to the salivary glands and can infect humans during 
the next blood meal. The lifecycle of the malaria parasite is described in Figure 1.2. It is 
during the RBC stage of the malarial cycle that clinical manifestations of malaria occur and 
continue until either the host immune response eliminates infection, it is cleared via 
antimalarial treatment [13] or the host dies. 
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Figure 1.2: Life cycle of Plasmodium falciparum. The life cycle begins when 1) the female 
Anopheles mosquito takes a blood meal 2) the parasite in the form of sporozoites travel via 
the bloodstream to the liver where they 3) invade hepatocytes and proliferate asexually into 
merozoites 4) upon release of merozoites they reenter the bloodstream and invade RBCs 
where they replicate asexually into merozoites and burst from RBCs to invade new RBCs 5) 
some merozoites form gametocytes and a mosquito may ingest them during their next blood 
meal thus continuing the cycle. Figure adapted from [14] by Farzin Adenwalla. 
 
1.4 Consequences of a Malaria Infection 
Malaria has many symptoms similar to the common cold and, with the hallmark pathological 
feature being fever, it often resembles viral infections. Symptoms common to fever such as 
nausea, chills, headaches and vomiting are present and it is therefore difficult to pinpoint a 
malarial diagnosis [15]. The clinical symptoms manifest during the asexual blood stage of 
the life cycle [16] (Figure 1.2 Step 4). After a period of symptoms where severity can vary, 
parasite load is controlled by the host’s immune response, although symptoms recur at 
intervals over weeks and months, associated with rises in parasitaemia [17]. The successive 
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waves of parasitaemia are lower and symptoms are less pronounced until eventually the 
infection is cleared [17]. 
In the case where malaria infection is not controlled, infection can progress to severe malaria 
(SM) which may result in death. P. falciparum is the predominant species causing SM in 
humans and accounts for over half a million deaths each year mainly in children in Sub-
Saharan Africa [18]. The main forms of SM  are different in children and adults in various 
epidemiological settings: 1) severe anaemia occurs in infants in areas of stable, intense 
transmission; 2) cerebral malaria and respiratory distress (as a result of metabolic acidosis) 
occur in young children in areas of moderate transmission and 3) cerebral malaria, organ 
dysfunction (e.g., renal failure, severe jaundice, and pulmonary oedema) and acidosis occur 
in individuals of all ages in areas of low and unstable transmission [19]. 
Various factors play a role in the pathophysiology of SM including exponential parasite 
growth and microvascular obstruction from adherence of mature parasites to blood vessels 
[20]. If the exponential phase increases by 10-fold every 48 hours, then total body 
parasitaemia is reached more rapidly [17]. This high parasite load triggers an acute 
inflammatory response and therefore SM arises due to excessive or poorly controlled 
responses that have evolved primarily to control acute infection [18]. Another key feature of 
SM is microvascular obstruction caused by P. falciparum sequestration of parasites within 
microvascular beds. This occurs via modifications on the RBC surface by the insertion and 
display of variant proteins such as P. falciparum erythrocyte membrane protein (PfEMP1) 
[21] which are able to bind to receptors on other cells including CD36 which is one of the 
well characterized receptors [22]. Infected cells can also bind to uninfected RBCs (uRBCs) 
(a process known as resetting) [23] and activated platelets, which lead to clumps. Both of 
these can lead to microvascular obstruction and SM.  
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1.5 Malaria Treatment 
Many drugs were developed to treat malaria in the 20th century, with chloroquine and 
artemisinin being the most widely-implemented and effective. However, with the rise in 
antimalarial resistance now threatening their efficacy, the need to discover novel antimalarial 
drug candidates are required [24].  
 
     1.5.1 Antimalarials 
The first line of treatment for uncomplicated  P. falciparum malaria in endemic areas is 
artemisinin combination treatment (ACT) [25]. ACT consists of an artemisinin derivative 
and a partner drug, which is another structurally unrelated antimalarial compound such as 
lumefantrine or mefloquine [26]. The mechanism behind artemisinin is based on the presence 
of the endoperoxide bond present in artemisinins, while their derivatives (as molecules 
without the endoperoxide bond) have no antimalarial activity [27]. This bond, in the presence 
of haem (from the degradation of host haemoglobin from the parasite) decomposes into free 
radicals [28]. These free radicals may then damage specific intracellular targets, possibly via 
alkylation [29]. The artemisinin derivative clears the majority of the parasites but it has a 
short half-life whilst the partner drug, has a longer half-life and targets parasites that remain 
in the system [30]. 
Another well-known antimalarial is chloroquine. At a physiological pH of ~7.4, chloroquine 
is a diprotic weak base and in its un-protonated state, is able to enter the digestive vacuole 
(DV) of the parasite within a RBC [31]. Within the DV, chloroquine molecules become 
protonated and accumulate inside the acidic DV as the membrane is not permeable to charged 
species [32, 33]. The protonated chloroquine subsequently binds to haematin, which is a toxic 
byproduct of haemoglobin proteolysis, thereby preventing haematin differentiating to the 
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haemozoin crystal [34]. Due to its inability to crystalize, free haematin interferes with the 
parasite detoxification processes thereby damaging the plasmodium membrane [35]. 
Due to antimalarial drug resistance (including chloroquine resistance), novel effective 
treatments are needed to combat malaria. [36]. The mechanisms behind drug resistance are 
spontaneous, and thought to be independent to the drug used; rather, it is thought to be due 
to mutations in genes encoding the drug’s parasite target or influx/efflux pumps that affect 
the intraparasitic concentrations of the drug [37]. One of these pumps involved in 
chloroquine transport is the P. falciparum chloroquine-resistance transporter (PfCRT). In the 
presence of a mutation, resistance occurs via a decrease in the concentration of chloroquine 
within the DV [38] due to the transport of drug away from the DV via PfCRT [39] and hence 
the site of action. The vital mutation seems to be the replacement of lysine with threonine at 
position 76 [40]. However, PfCRT is not the sole determinant of chloroquine resistance, as 
it has been shown  that mutations in the homolog of the major multidrug-transporter P. 
falciparum multidrug gene also modulates the extent of resistance [38]. 
 
     1.5.2 Vaccine Protection 
In terms of vaccines, RTS,S/AS01 is the most advanced P. falciparum vaccine candidate 
developed globally [41]. The vaccine consists of hepatitis B surface antigen virus-like 
particles and incorporates a portion of the P. falciparum-derived circumsporozoite protein 
and a liposome-based adjuvant [41]. The vaccine targets the circumsporozoite protein of  
P. falciparum to induce specific CD4-positive T cells that are associated with protection to 
P. falciparum infection and episodes of malaria [42, 43]. In a 2009 study of 15,000 infants 
and young children from Sub-Saharan Africa, in infants aged 6-12 weeks and young children 
5-15 months, the efficacy of the vaccine decreased rapidly [44].  A booster shot 20 months 
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after the initial dose increased protection slightly. Individuals in the 5-17 month group 
contracted meningitis compared to children who received control vaccines [45].  
Another vaccine that seemed promising and underwent early phase I/IIa clinical trials was 
using the radiation-attenuated, whole-cell sporozoite vaccine which delivered sterile 
protection against injection with sporozoites of the same parasite strain [46]. However, this 
vaccine had drawbacks including lack of cross-strain protection, high numbers of parasites 
required, route of delivery and the logistical requirements for a liquid nitrogen cold chain to 
maintain viability of vaccine [46]. Despite these drawbacks, the ultimate goal for a successful 
vaccine is to induce strain-transcendent protection [17]. 
 
1.6 Host Response to Malaria 
Malaria is the strongest known selective pressure on the human genome in recent history 
[47]. Genetic polymorphisms such as sickle cell anaemia [47] and Duffy negativity [48] in 
their asymptomatic heterozygous form, confer resistance to the malaria parasite providing an 
evolutionary advantage for these polymorphisms and, along with the host response, play an 
important role in controlling infection. Along with these genetic polymorphisms, two lines 
of host immune defence play a role in combating malaria infection; innate immune system 
and the adaptive immune system. 
 
     1.6.1 Resistance to Malaria: Genetic Polymorphisms 
Genetic polymorphisms have been shown to confer resistance to malaria and have been 
associated as an evolutionary force for genetic traits such as sickle cell disease [49] and Duffy 
negativity [48]. Sickle cell disease results when there is a substitution of valine for glutamic 
acid at its sixth amino acid of the β-globin chain [50]. Individuals homozygous for the 
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mutation develop symptomatic, and potentially deadly sickle disease whereby the 
polymerized haemoglobin causes RBCs to become sickle shaped and occlude blood vessels, 
whilst heterozygous individuals have sickle cell trait and are generally asymptomatic [51]. 
Sickle cell trait confers resistance to malaria [52] and the frequency of carriers of this trait is 
high in malaria endemic regions, furthering evidencing the evolutionary advantage and 
history of sickle cell disease with malaria prevalence  [53]. Resistance is thought to be due 
to parasitised mutant polymorphic RBCs subjected to enhanced phagocytosis by monocytes 
which suggests P. falciparum is cleared by the immune system more rapidly [54]. 
Progressive dehydration of RBCs and increased cellular density have also been associated 
with decreased invasion by P. falciparum suggesting that structural features of the host cell 
play a role in resistance [55]. 
The Duffy-negative red cell phenotype is another well-known polymorphism that can cause 
malarial resistance. The Duffy antigen encodes a chemokine receptor (DARC, also known 
as Fy) and is expressed on the RBC surface. A polymorphism at a GATA-1 binding site in 
the promotor of the DARC gene alters receptor expression, leading to no expression on the 
RBC surface [56]. Almost all Central and West African people are Duffy-negative and as 
such these individuals are resistant to Plasmodium vivax infection which requires Duffy to 
invade the RBC [57].  
Understanding the variability of genes in human populations, and how they may provide 
resistance against malaria, may provide greater insight into developing new interventions, 
therapies and working towards  better management of malaria.  
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     1.6.2 Innate Immune System 
The innate immune system comprises of cells such as natural killer cells and dendritc cells. 
This is the first line of defence in regard to bacteria [58], virus [59] and parasite [60] invasion. 
Studies in mice and humans show the important role of macrophages in phagocytosing 
iRBCs in the absence of cytophilic or opsonizing malaria-specific antibody [61]. This 
interaction of iRBCs is possibly due to the presence of CD36 on the surface of various cell 
types which subsequently results in sequestration of parasites in the microvascular endothelia 
[62]. 
Furthermore, studies in mice have found that cytokines, such as interferon-γ, are released 
within the first few hours of a malaria infection, and subsequently predict the course of 
infection and its final outcome [63, 64]. Interferon-γ is an important pro-inflammatory 
cytokine [65] and it plays a protective role against infection by protozoan parasites [66, 67]. 
The production of interferon-γ in naïve animals may result from either pre-existing, cross-
reactively primed effector memory T-cells or from cells of the innate immune system, e.g. 
phagocytic granulocytes, macrophages, Natural Killer cells or γδ T-cells [68].  
Platelets constiture an important part of the innate immune system defense against malaria. 
Although the traditional role of platelets is in haemostasis and thrombosis, platelets have 
been recently defined as an immune cell and have been shown to play a role in malaria by 
killing the parasite which resides within the RBC [69, 70]. The role of platelets in malaria 
infection is discussed further in Section 1.9. 
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     1.6.3 Adaptive Immune System 
The adaptive immune system consists of cells such as B and T lymphocytes. Mechanisms of 
the adaptive immune system that play a role in parasite defense include antibodies blocking 
hepatocyte invasion, antibodies binding to adhesion molecules on the vascular endothelium 
thus preventing sequestration of iRBCs, and antibodies blocking merozoite invasion into 
RBCs [71].  
When immune adults leave malaria-endemic regions, their immunity to malaria wanes 
quickly, which suggests that continued exposure to malarial antigens is needed not only for 
the generation of memory cells and effector cells but also for their persistence [72]. Rapid 
boosting of antibody responses to various antigens after reinfection does take place which 
indicates the presence of memory B cells [72].  
 During the erythrocytic stage of infection, CD4+ T-cells can play a protective role via 
interferon-γ production. CD4+ T-cell help is also required for the B-cell response which is 
involved in control and elimination of infected red blood cells [73]. CD4+ T-cells are also 
important for controlling  pre-erythrocytic stages of Plasmodium infection through the 
activation of parasite-specific CD8+ T-cells [73] which are a subpopulation of MHC class-I 
restricted T cells and mediators of adaptive immunity.  
 
1.7 Platelets  
Platelets have been well described for their role in haemostasis and thrombosis [74], 
however, in recent times, the versatility of platelets has recently been discovered due to their 
ability to interact with invading pathogens [75]. Platelets interact with pathogens using 
receptors that are present on classical immune cells such as Toll-Like Receptors (TLRs), 
CD40 and ICAM-2 [76].  
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The following section discusses not only their traditional role as initiators of clotting but also 
how platelets play a role in the immune system, their role in a malaria infection and how a 
loss of platelets during a malarial infection is commonly observed (known as 
thrombocytopenia). 
 
     1.7.1 Traditional Role of Platelets 
The “father of the platelet” was Giulio Bizzozero, who in 1862, described a novel 
morphological element in the blood that played a crucial role in haemorrhage and thrombosis 
[77], and was later termed 'platelet'. Platelets are anuclear cells and the smallest cells within 
the blood, ranging from ~2-5 µm in diameter and 0.5 µm in thickness [78]. They are produced 
from megakaryocytes in the bone marrow and after being released into circulation, have a 
life span of around 7-10 days in humans [79]. 
In healthy vasculature, platelets are kept in an inactive state via nitric oxide and prostacyclin 
which are released by endothelial cells that line the blood vessels [80]. However, when a 
vascular injury occurs, collagen and basement membrane proteins are exposed that allow 
platelets to adhere to the substratum [74]. Platelets then adhere and aggregate and release 
platelet activation factors such as adenosine diphosphate and thromboxane A2 and, following 
activation, platelets produce thrombin catalyzing the coagulation cascade, eventually 
generating a mesh like structure that stops bleeding [74]. The role of platelets in the formation 
of a blood clot is described in Figure 1.3. 
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Figure 1.3: Role of platelets in clotting. Vascular injury occurs exposing collagen and 
extracellular matrix proteins 1) activated platelets adhere to site of injury due to the exposure 
of collagen and 2) aggregate and release other factors such as adenosine diphosphate, 
thromboxane A2 and thrombin which in turn activates more platelets 3) thrombin turns 
fibrinogen into fibrin which forms a meshlike structure and stops bleeding. Adapted from 
[74] by Farzin Adenwalla 
    
  1.7.2 Platelets as Regulators of the Immune Cell 
Besides their role in haemostasis and thrombosis, platelets exert immunological functions 
and participate in the interaction between pathogens and host defense due to their binding 
ability since they have a broad repertoire of receptor molecules [75]. For example, CD154 is 
a transmembrane protein that is expressed by CD4+ T cells, however in 1998, Henn and 
colleagues found that CD154 was also expressed by activated platelets [81] and binds to 
CD40. CD40 was first described on human bladder carcinoma cells [82] but is also expressed 
on B lymphocytes, monocytes, dendritic cells and endothelial cells [83]. Interaction of 
CD154 and CD40 on endothelial cells induces various inflammatory responses including the 
expression of  inflammatory adhesion receptors such as intercellular adhesion molecule 1 
(ICAM1) and vascular cell adhesion molecule 1 [84].  
1 2 3 
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Platelets also express TLRs which are a class of pattern recognition receptors able to detect 
distinct evolutionarily conserved structures on pathogens (termed PAMPs – pathogen 
associated molecular patterns) [85]. TLRs are also expressed by neutrophils, macrophages 
and dendritic cells which highlight the role of various TLRs in both innate and adaptive 
immune responses. Human platelets for example, have been shown to express TLR1, TLR2, 
TLR4, TLR6, TLR8, and TLR9 and TLR3 [86, 87] and platelet expressed TLRs act as a 
bridge between platelets and inflammatory responses further illustrating the intricate 
interactions between innate and adaptive immunity [87, 88]. TLR4 is one of the most 
extensively studied TLRs on human platelets [89]. An example of the role of TL4 between 
platelets and infection occurs by interacting with lipopolysaccharides from gram-negative 
bacteria which are able to activate platelets and induce platelet-neutrophil interactions 
leading to neutrophil degranulation and release of extracellular traps which in turn can kill 
bacteria [90].  
 
1.8 Molecular Mechanisms of P. falciparum Adhesion 
Due to parasite-derived adhesins expressed on the surface of mature iRBCs, they are able to 
adhere to various receptors and be sequestered [91]. Three types of adhesions have been 
described; cytoadherence to endothelial cells [92], rosetting with uRBCs [93] and 
interactions with platelets that can lead to clumping of iRBCs in vitro [94]. The cloning of 
the var genes encoding the variant surface antigen family PfEMP1 in 1995 provided the 
groundwork for the molecular basis of adhesion in P. falciparum malaria [95-97]. The 
variants are expressed on the surface of the iRBC and are responsible for some of the 
adhesive properties of iRBCs. Some of the receptors that promote adhesion are discussed 
below. 
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     1.8.1 CD36 
iRBCS are able to bind to the scavenger receptor CD36 which is expressed on macrophages, 
epithelial cells, monocytes, RBC precursors and platelets [98]. PfEMP1 variants are the 
parasite-induced iRBC ligands for CD36, and CD36 binding is a characteristic of almost all 
P. falciparum isolates derived from malaria patients. CD36 is a key element in innate defense 
due to the diverse range of cells CD36 is expressed by [61]. In dermal microvasculature, 
iRBC adhesion to CD36 may help to create a microenvironment that enhances parasite 
replication, at least in murine parasites such as P. berghei [99].  
It has been observed that platelet activation can occur when iRBCs bind to CD36 on platelets. 
When platelets were incubated with control RBC or P. falciparum, iRBCs pre-treated with 
Fab fragments of non-specific IgG or a CD36 blocking antibody, there was a significant 
increase in platelet activation as determined by increased binding of anti-PAC1  [100] which 
recognizes the fibrinogen binding sites in the glycoprotein IIb/IIIa (also known as CD41) 
complex of activated platelets. The binding of iRBC to platelets has been shown to release 
platelet factor 4 which has been implicated in parasite killing [69, 70]. 
 
     1.8.2 ICAM1 
ICAM1 belongs to the immunoglobulin superfamily expressed on endothelial cells and 
leukocytes [91]. Research using isolates from patients found that ICAM1 mediated rolling 
adhesion, while CD36 mediated stationary adhesion, suggesting that ICAM1 capture and 
CD36 stationary adhesion [101] may work together to promote efficient sequestration. In a 
malaria infection, there are elevated serum levels of the soluble form of ICAM1 [102, 103] 
and post-mortem tissue samples have demonstrated widespread systemic upregulation of 
ICAM1 expression at microvascular endothelial sites [104, 105]. 
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     1.8.3 CD62P 
CD62P is a glycoprotein that is expressed on activated platelets and endothelial cells, and is 
important for leukocyte trafficking [91]. From field isolates in Thailand, CD62P has been 
shown to mediate rolling of iRBCs on endothelial cells, and facilitates adhesion [106, 107]. 
The parasite ligand for CD62P is thought to be PfEMP1 since purified PfEMP1 can bind to 
CD62P in vitro [108]. 
 
     1.8.4 Thrombospondin 
Thrombospondin is an adhesive glycoprotein that is released into plasma in response to 
platelet activation by thrombin [91]. It was the first molecule associated with P. falciparum 
cytoadherence.  It has previously been shown that iRBCs bind to purified thrombospondin 
in static assays [109], and bind to endothelial cells via thrombospondin under flow conditions 
[110]. 
 
1.9 Platelets During a Malaria Infection 
During malaria infections, it has been found that platelets played a protective role by killing 
the parasite [70, 111]. Evidence for the protective effect of platelets resulted from a study 
using mice that were deficient in platelets [70]. Mice that display a homozygous disruption 
of Mpl which encodes for the megakaryocyte growth and differentiation factor C-mpl (the 
receptor for thrombopoietin), ended up with only 1/10th as many platelets as their wild-type 
counterparts [112]. When these mice were infected with the mouse malaria strain P. 
chabaudi, Mpl-/- mice had a lower survival rate than wild-type mice [70] (Figure 1.4a and 
1.4b). 
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Figure 1.4: Survival curve of mice infected with Plasmodium chabaudi. Mice were 
infected with P. chabaudi and survival rates monitored in a) male mice b) female mice [70]. 
 
In vitro studies were also carried out to demonstrate platelet protection using a P. falciparum 
culture. When human platelets at increasing concentrations were cultured with purified with 
P. falciparum at trophozoite stage, a concentration-dependent increase in the inhibition of 
parasite growth was observed (Figure 1.5a). Aspirin inhibits platelet cyclooxygenases which 
results in a decrease in thromboxane A2 and therefore decreased platelet activation [113]. 
When platelets were incubated with aspirin, the killing effects of platelets on parasites were 
no longer present. (Figure 1.5b), further confirming platelet-mediated parasite killing [114]. 
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Figure 1.5: Percentage of growth inhibition with purified human platelets. a) Parasite 
growth inhibition with increasing concentrations of purified platelets. Chloroquine was used 
as a positive control. b) Parasite growth in the presence of platelets preincubated with aspirin 
before being added to parasite culture (in vitro aspirin) or untreated platelets (control) 
compared with platelets taken from the same donor on separate occasions after taking aspirin 
twice daily for one week before platelet collection (in vivo aspirin) [70]. 
 
More evidence in the above study of platelet protection playing a role in the protection 
against P. falciparum was via the use of terminal deoxynucleotidyl transferase deoxyuridine 
triphosphate nick end labeling (TUNEL) which stains for degraded DNA. Twice as many 
dead intraerythrocytic parasites were seen in wild-type mice compared to the mutant mice 
(Figure 1.6a) which suggested platelets play a role in the killing of the parasite. TUNEL-
stained intracellular parasites were also observed in the P. falciparum cultures where the 
frequency of stained parasites was more than three times as high in platelet-treated cultures 
(Figure 1.6b).  
 
 
 
a 
 
a 
b 
 
a 
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Figure 1.6: Intraerythrocytic parasites are killed by platelets. a) Percentage of all P. 
chabaudi parasites staining positive with TUNEL in mice wild-type and mutant mice. b)  
Percentage of TUNEL-positive parasites in P. falciparum cultures incubated with platelets 
and without platelets for 24 hours [70]. 
 
1.10 Platelet Factor 4 
The molecule associated with the killing of the parasite via platelets was identified   as 
platelet factor 4 (PF4) [69, 111]. PF4 is a platelet derived CXC-type chemokine which is 
released from the α-granules upon platelet activation [115]. PF4 is a human defense peptide 
that has antimicrobial activity to pathogens including bacteria [116] and fungi [117]. 
The mechanism of action of PF4 was shown to be via lysis of the DV [69]. The DV is the 
site where the parasite obtains essential amino acids and energy in order to survive, and it 
appears that PF4 works solely on the DV, as the parasite plasma membrane is undisturbed, 
as is mitochondrial function [69]. 
PF4 does not work alone but needs the Duffy antigen to initiate the killing mechanism. The 
Duffy protein has been identified as a receptor for chemokines and hence has been named 
Duffy antigen receptor for chemokines (DARC) [118]. It is expressed on the RBC surface 
and, when parasites where cultured in Duffy negative blood, parasite growth was unaffected 
by platelets or PF4 treatment [111]. Likewise, when chemokines were used with a higher 
a b 
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affinity to Duffy than PF4, or when monoclonal antibodies that block PF4 binding were used, 
it blocked the ability of PF4 to kill parasites suggesting PF4 was the parasite killing molecule.  
 
1.11 Thrombocytopenia 
In 1924, it was reported that platelet numbers in malaria-infected individuals were reduced 
in the peripheral blood of patients with acute malaria [119]. The decrease in platelet number 
is known as thrombocytopenia, characterised by a platelet count less than <150,000/mm3 
[120].  
In a malaria infected individual, thrombocytopenia is commonly observed and can be a result 
of platelet activation, splenic pooling, or a decreased platelet life-span due to antibody and 
cellular immune responses [120]. On rare occasions, thrombocytopenia may result from 
antibodies produced against antimalarials, interacting with platelets [121]. In most cases, 
bleeding is not associated with thrombocytopenia and requires no treatment, with platelet 
count returning to normal after successful treatment of the malarial episode [122]. 
Along with anaemia, thrombocytopenia is the most frequent malaria-associated 
haematological complication observed [123] as concentration of platelets have been shown 
to be inversely correlated with the level of parasitaemia. Thrombocytopenia has been shown 
to occur early in infection in both humans and mice before severe forms of the disease 
develop [70, 124], therefore thrombocytopenia is an excellent diagnostic tool for those 
returning from an endemic region. 
It has been previously shown in human [124], mouse [70] and monkey [125] models of 
malaria that a loss of platelets accompanies an increase in parasitaemia.  In mice infected 
with P. chabaudi, the relationship between platelet concentration and parasitaemia is inverse 
and is shown in Figure 1.7. A decrease in platelet concentration is observed as concentration 
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of parasites increase, however RBC concentration remains constant; thus, thrombocytopenia 
is noted before the symptoms such as anaemia is observed. Platelet numbers also reached the 
lowest point before the onset of severe disease symptoms and anaemia. 
 
 
 
 
 
 
 
 
 
 
Figure 1.7: Thrombocytopenia in mice infected with P. chabaudi. An inverse relationship 
between platelet concentration (green) and parasitaemia (blue). Red blood cell levels stay the 
same during infection (red) [70]. 
 
Another study, conducted in 1983 by DeGraves and colleagues [126] observed rats infected 
with P. chabaudi. This study showed there was an association with infection and decreased 
numbers of RBCs and platelets with increasing percentage of parasitised cells. When parasite 
numbers were reduced to a level not detectable, anaemia seemed to persist for several weeks 
whereas thrombocytopenia was no longer observed. 
Another malaria model investigating thrombocytopenia was conducted on monkeys. It has 
been observed that severe thrombocytopenia developed in Aotus monkeys [125] infected 
with P. vivax. From 26 monkeys, 77% developed severe thrombocytopenia and showed an 
inverse relation to parasitaemia. 
 
a 
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In human studies, healthy individuals were infected with P. falciparum, and showed a 
significant decrease in platelets between five-six days after the onset of blood stage infection 
(Figure 1.8). With this decrease in platelet number, levels of von Willebrand factor (vWF – 
a marker of chronic endothelial activation) and vWF propeptide (a marker of acute 
endothelial activation) significantly increased at a very early stage in infection which suggest 
acute endothelial cell activation early in malaria [124]. The authors hypothesised that 
endothelial cell activation with subsequent release of activated vWF is related to the 
development of early thrombocytopenia. Increased amounts of activated vWF which expose 
the glycoproteinIba-binding site of vWF for platelets were also observed. Platelet numbers 
and levels of both vWF and activated vWF showed a strong inverse correlation in the 
volunteers. Activated vWF may therefore be an important inducer of thrombocytopenia 
during early malaria and may contribute to the pathogenesis of malaria. 
 
 
 
 
 
 
 
 
 
Figure 1.8: Thrombocytopenia in healthy human volunteers infected with  
P. falciparum. Percentage of platelet baseline during infection from healthy individuals 
infected with P. falciparum. A significant difference was seen on days five and six. [124]. 
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Altogether, the above models suggest that thrombocytopenia does indeed occur during a 
malaria infection, the exact mechanism of malaria-induced thrombocytopenia has not been 
elucidated. A number of proposed mechanisms have been investigated and some of these are 
discussed in the following section. 
 
1.12 Mechanisms of Thrombocytopenia 
A number of possible mechanisms of malaria-induced thrombocytopenia have been 
postulated. Splenic pooling, liver sequestration, endothelial activation, platelet consumption 
and platelet binding to RBCs have been proposed, although the exact mechanisms are still 
under investigation.  
 
     1.12.1 The role of the spleen in malaria induced thrombocytopenia 
 In 1973, Skudowitz and colleagues suggested that platelets were sequestered in the spleen 
during an acute infection. Within the hematopoietic system, the spleen is an important 
structure as it stores 1/3 of the platelets that are produced by the bone marrow whilst the 
remaining are in circulation [127].  
In a malaria infected individual, an increase in spleen size is commonly noted, as well as in 
subjects who are often exposed to malaria. The spleen is known to clear away infected RBCs, 
and splenectomised patients usually show an increase of parasitaemia during a P. falciparum 
infection regardless of the antimalarial agent used, showing the crucial importance of the 
spleen in parasite clearance [121]. 
In a P. chabaudi infection, where mice were splenectomised, thrombocytopenia was absent 
which reinforced the idea that the spleen was important in thrombocytopenia [128]. 
However, in 2004, Karanikas et al [129] evaluated the platelet kinetics and sequestration site 
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by isotopic studies in uncomplicated malaria-induced thrombocytopenia. Although they 
showed that platelet lifespan was reduced, recovery was normal, and the platelet turnover 
rate was enhanced, the sequestration site of uncomplicated malaria-induced 
thrombocytopenia appeared to be non-splenic. This, therefore, refuted the original hypothesis 
that malaria-induced thrombocytopenia was splenic. Another piece of evidence that supports 
the idea that thrombocytopenia is non-splenic is that when five Rhesus monkeys were 
inoculated with sporozoites of P. cynomolgi, two of which had their spleens removed, all five 
monkeys showed a significant fall in platelets correlating with maximum parasitaemia [130]. 
There was no difference between those with and without their spleens, with platelet levels 
returning to normal levels two to six days later.  
 
     1.12.2 The role of the liver in malaria induced thrombocytopenia 
Another possible organ responsible for thrombocytopenia is the liver. The relationship 
between the liver and platelets is strong, as the liver is the source of thrombopoietin (the 
glycoprotein made in the liver responsible for platelet production in the bone marrow) [131]. 
The earliest stage of the innate immune response to infection is the acute-phase response 
resulting in the production of acute-phase protein by the liver [132]. Stimulators of acute-
phase proteins production include IL-1β and TGF-β which are platelet-derived immune 
mediators. Activated platelets express adhesion molecules such as P-selectin which interacts 
with lectin receptors on hepatic sinusoids to induce the production of acute-phase proteins, 
indicating that platelets may play a role in the induction of the acute-phase response [132]. 
In a P. berghei model it was found that platelets are activated early during blood stage 
infection and platelets initiate the acute-phase response [132]. In this experiment, mice were 
infected with P. berghei and 24 h post-infection, mice were injected intravenously with 
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fluorescently labelled anti-platelet antibodies. Mice were then euthanized, livers thinly sliced 
and imaged on a fluorescent microscope (Figure 1.9a). Infected mice had ∼3-fold more 
platelet foci in liver sections compared with uninfected controls, indicating an increase in 
platelet trafficking to the liver during acute-phase response induction (Figure 1.9b).  
 
 
 
 
 
 
 
 
Figure 1.9: Platelet recruitment to the liver post- P. berghei infection. a) Platelets (white 
arrows) are recruited to the liver post infection compared to control. b) Platelet foci were 
quantified from 10 different fields [132]. 
 
     1.12.3 Platelet Consumption and Endothelial Activation 
Platelet consumption (as a result of platelet activation) is hypothesised to be one mechanism 
of malaria-induced thrombocytopenia in humans. Adenosine diphosphate can cause 
activation and aggregation [133] and it has been suggested that when adenosine diphosphate 
is released during erythrocytes haemolysis in a malaria infection, platelets are activated and 
in turn are cleared away by the spleen [134].  
Another proposed mechanism of malaria-induced thrombocytopenia regarding platelet 
consumption can be a result of disseminated intravascular coagulation (DIC). DIC is a 
condition in which small blood clots develop throughout the bloodstream, blocking small 
blood vessels which in turn can deplete platelets due to increased clotting [135]. In a study 
of 21 patients [136] with falciparum malaria, six developed DIC. The authors observed that 
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the patients with more severe thrombocytopenia also had DIC and that there was a correlation 
between platelet count and C3 protein levels, with the reduction in C3 proportional to that of 
parasitaemia. This suggested that thrombocytopenia was not independently associated with 
C3 (a protein of the immune system that plays a role in the complement system and 
contributes to innate immunity) [137]. In 2004, a study with P. falciparum and P. vivax 
patients demonstrated a negative correlation between platelet counts, thrombin-anti-
thrombin complex and D-dimers which are DIC markers, suggesting that the activation of 
coagulation could be partially responsible for thrombocytopenia [138]. 
 
     1.12.4 Platelet Binding to Red Blood Cells 
Previous studies have shown that platelets can bind to uRBCs and iRBCs [70, 139]. In mice 
that were infected with P. chabaudi, when parasitaemia was ~10-15%, the proportion of 
platelets bound to iRBC was greater than that of platelets bound to uRBCs. CD41 (a platelet 
surface marker) on the surface of RBC was used as a marker for detecting platelet-bound 
RBCs. There were three times as many infected CD41 positive RBCs compared to uRBCs, 
indicating that platelets preferentially bound to iRBCs (Figure 1.10a). Similar results were 
seen with cultured P. falciparum with twice the number of infected RBCs bound by human 
platelets compared to uRBCs (Figure 1.10b). Therefore, the aim of Chapter 4 was to measure 
the contribution platelet binding played towards thrombocytopenia in a mouse model of 
malaria. 
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Figure 1.10: Platelet binding to infected and uninfected red blood cells. a) Platelets bind 
three times more to infected RBCs than uninfected RBCs in mice (P <0.05) b) Platelets bind 
two times more to infected RBCs than uninfected RBCs in in vitro human-model assay (P < 
0.01) [70]. 
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Hypothesis 
The first hypothesis of this thesis was that iRBCs express or secrete molecules(s) unique to 
the iRBC and not to uRBCs. The molecule(s) that attract platelets and induce subsequent 
activation and release of PF4 onto the surface of the infected RBC was to be determined.  
 
The second hypothesis was that platelet binding to iRBCs contributed to thrombocytopenia 
in a mouse model of malaria.  
 
The following aims were carried out to test the above hypotheses.  
 
Project aims 
• To determine the protein(s) involved in activating platelets when platelets are 
incubated with iRBCs at the trophozoite stage (chapter three). 
• To investigate thrombocytopenia in a mouse model of malaria using flow cytometry 
by measuring platelet, RBC and platelet bound RBC concentrations (chapter four). 
• To determine platelet clearance during an infection (chapter four). 
• To determine if platelet complexes contribute to the loss of free circulating platelets 
and ultimately contribute to thrombocytopenia (chapter four). 
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Chapter 2 Materials and Methods 
 
2.1 Materials for Human Platelet Activation Studies 
 
2.1.1 10x Platelet Wash Buffer 
43 mM   K2HPO4   
43 mM  Na2HPO4   
243 mM  NaH2PO4   
1.13 M   NaCl    
55 mM  Glucose   
pH should be ~6.8, filter sterilised and stored at -20oC. 
 
2.1.2 1x Platelet Wash Working buffer (PWB) – made fresh on the day 
1x platelet wash buffer, 10mM theophylline (Simga-Aldrich), 0.35% (w/v) human serum 
albumin (Sigma-Aldrich). 
 
2.1.3 10x Tyrode Solution   
1.34 M  NaCl         
120 mM  NaHCO3        
29 mM  KCl        
3.4 mM  NaH2PO4.2H2O (monobasic)     
10 mM  MgCl2        
50 mM  HEPES        
50 mM  Glucose     
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pH should be 7.35, filter sterilized and stored at -20oC.  
 
2.1.4 Tyrode working buffer - made fresh on day of prep 
0.35% (w/v) human serum albumin, 1x Tyrode solution. 
 
2.1.5 10x Human Tonicity Buffer (HTB) 
4 mM   NaH2PO4.H2O         
16 mM  Na2HPO4.2H2O        
120 Mm  NaCl   
 
2.1.6 FACS Buffer 
1x HTB containing 1% Bovine Serum Albumin (Sigma-Aldrich). 
 
2.1.7 Hypotonic Lysis Buffer      
50 mM   Hepes pH 7.5 
0.5 M   KCl   
5 mM   Dithiothreitol  
50 mM  Lysine 
3 mM   MgCl2 
 
2.1.8 10x RPMI 
Add one sachet of RPMI 1640 Medium (Thermo Fisher Scientific) to 80 mL milliQ water 
and top up to 100 mL when dissolved.   
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2.1.9 90% Percoll 
Make up 90% Percoll (v/v) from 100% Percoll (Sigma-Aldrich) in 10x RPMI. 
 
2.1.10 70% Percoll 
Make up 70% Percoll v/v solution from 90% Percoll solution in RCW/Sorbitol. 
 
2.1.11 Phosphate Buffered Saline (PBS) 
137mM  NaCl   
2.7mM  KCl  
8.1mM  Na2HPO4 
pH 7.2-7.4, 0.2µm filter sterilized. 
 
2.1.12 Red Cell Wash/Sorbitol 
13.3% (w/v)   Sorbitol   
10mM   Sodium phosphate,  
160mM  NaCl 
pH 7.4 and filter sterilized. 
 
2.1.13 PF4 ELISA Wash Buffer  
0.05%  Tween™ 20 (Sigma-Aldrich) in PBS 
 
2.1.14 Reagent Diluent 
1% Bovine Serum Albumin (Sigma-Aldrich) in PBS pH 7.2-7.4, 0.2µm filter sterilised. 
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2.1.15 Stop Solution 
2 N    H2SO4 
 
2.2 Materials for Mouse Models of Thrombocytopenia Studies 
 
2.2.1 Citrate Buffer 
97 mM   Na3C6H5O7  
43 mM  C6H8O7   
243 mM  C6H12O6  
Citrate buffer was stored at 4ºC. 
 
2.3 Methods for Human Platelet Activation Studies 
 
2.3.1 Human Platelet Purification 
Human platelets were obtained from freshly drawn blood from volunteers on the day of the 
experiment by an experienced phlebotomist and according to the ANU ethics protocol 
2014/732 and Macquarie University ethics protocol 5201200714. Collection of blood was 
into BD Vacutainer™ Plus Plastic Citrate tubes (BD Biosciences) and subsequently 
centrifuged for 13 mins at room temperature (RT) (23ºC) with brakes set at zero. After 
centrifugation, platelet rich plasma (PRP) was carefully pipetted into pre-warmed 15 mL 
falcon tubes and left to rest at 37ºC for 30 mins. PRP was subsequently centrifuged for a 
further seven mins at 1700g to pellet platelets. After the centrifugation, the supernatant was 
carefully removed to ensure minimal disruption to the platelet pellet. The platelet pellet was 
then washed in an equal volume of platelet wash buffer and left to rest at 37ºC for a further 
30 mins. One final centrifugation step at 1500g for seven mins was carried out. The 
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supernatant was removed and the platelet pellet was resuspended in 500µL Tyrode’s Buffer 
containing a final concentration of ADPase at 0.02U/ml. A diluted sample of platelets was 
run on the ADVIA 120 Hematology System (Siemens) to measure platelet concentration and 
baseline platelet activation levels using mean platelet volume and mean platelet component 
measurement. 
2.3.2 Plasmodium falciparum Culture 
The human malarial species P. falciparum 3D7 laboratory strain was used for human platelet 
activation studies. 3D7 parasites were cultured with blood donated by the Australian Red 
Cross, to a maximum of 10% parasitaemia and 2% haematocrit in Complete Culture Medium 
(CCM) (Sigma-Adrich). Cultures were fed every second day to remove waste products, 
retain correct pH and provide fresh nutrients to the parasites. This was done by transferring 
the culture to sterile centrifuge tubes and centrifuged at 500g for five mins (brakes up 5, 
down 3) at RT. The supernatant was removed and replaced with fresh media. To split the 
cells to a desired level of parasitaemia, an appropriate volume of parasitised cells were mixed 
with fresh uninfected blood to a final haematocrit of 2% using the below calculation. Cultures 
were maintained in sealed flasks filled with a gas mixture (1% O2/5 % CO2 in N2) and 
incubated at 37 oC, shaking at 50rpm. 
Amount of infected of blood required = (% parasitaemia required/current % parasitaemia)* 
total volume of blood 
Amount of fresh blood required = total volume of blood – amount of infected blood  
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2.3.3 Giemsa smears: Human Blood 
In order to determine parasitaemia, 100µL of P. falciparum culture was centrifuged to pellet 
infected blood. 80µL of supernatant was removed and the remaining media was used to 
resuspend the pellet. A smear was made using the blood and was then subsequently fixed in 
methanol for 45 secs. The slide was left to air dry and stained in Giemsa for 20 mins, before 
air-drying again, and visualizing under a light microscope.  
 
2.3.4 Percoll Gradient 
When parasitaemia reached 5-10% trophozoite stage (as determined via Giemsa stain), a 
Percoll gradient was used to purify trophozoite stage RBCs to use in subsequent experiments 
(section 2.3.6). Culture was decanted into a 50mL falcon tube and centrifuged for five mins 
at 500g (brakes up 5 down 3). The supernatant was removed and the infected RBC pellet was 
gently layered on top of 70% percoll and centrifuged for 10 mins at 3500rpm (brakes up 3 
down 0). Three layers were seen after the centrifugation; ring stage and uRBCs at the bottom, 
middle layer of percoll and only the top layer was the trophozoites. The top layer was 
carefully pipetted and used for platelet activation assays.  
 
2.3.5 Whole Protein Purification 
When parasitaemia reached 5-10% trophozoite stage, tropohozoite stage RBCs were purified 
as per section 2.3.4 and resuspended in 20 vols of ice-cold hypotonic lysis buffer containing 
cOmplete, Mini, EDTA-free tablets (Roche). Three cycles of freeze thawing in dry ice was 
carried out and the samples were centrifuged at 10,000g for 15 mins. Supernatants were 
removed and pellets were washed in buffer and, after the final wash, stored in aliquots at -80 
oC. 
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2.3.6 Platelet Activation Assay 
Purified human platelets (300µL) collected as described in section 2.3.1 were incubated at 
37ºC with either trophozoite stage RBCs (Section 2.3.4) or infected lysate from hypotonically 
lysed iRBCs collected as described Section 2.3.5. 100µL was fixed with 1% cytofix (BD 
Biosciences; diluted 1/4 in PBS to achieve 1%) to stain with anti-CD62P-FITC (AK4, 
BioLegend) prior to flow cytometry (Section 2.3.8), 100µL was stained with 10µg/mL  
anti-PAC1-FITC (PAC1, BioLegend) for 45 mins at 37ºC and fixed with 1% cytofix and the 
remaining 100µL centrifuged at 1000g for two mins supernatant was collected and kept at -
80ºC for PF4 detection. 
 
2.3.7 Platelet Factor 4 ELISA 
PF4 detection was carried out using the commercially available Human CXCL/PF4 DuoSet 
ELISA (R & D systems). Briefly, 96-well plates were coated with capture antibody by 
incubating overnight at RT. Wells were aspirated and then washed with PF4 ELISA wash 
buffer (3x 400 µL) and blocked with 300µL of reagent diluent. A subsequent washing step 
was carried out. 100µL of sample was added to each well before being incubated for two 
hours at RT and then washed. 100µL of detection antibody was added, incubated for two 
hours at RT and washed. 100µL of Streptavidin-HRP was added to each well and left covered 
in the dark for 20 mins at RT and subsequently washed. 100 µL of substrate solution  
(1-Step™ Turbo TMB-ELISA) (BioRad) was added to each well, left in the dark for 20 mins 
and washed. In order to stop the reaction, 50µL of stop solution was added to each well. The 
SpectraMax 190 Microplate Reader (Molecular Devices) was immediately used to measure 
the optical density at 450 nm. 
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2.3.8 Flow Cytometry Staining 
Samples fixed for CD62P (Section 2.3.6) staining were centrifuged for two mins and fixation 
buffer was removed carefully to not disrupt the platelet pellet. The pellet was resuspended 
with 500µL FACS buffer and centrifuged for two mins at 1000g. FACS buffer was removed 
and the pellet resuspended in 50µL FACS buffer containing 20µg/mL  
anti-CD62P-FITC on ice for ~30 mins. 1mL FACS buffer was added and centrifuged for two 
mins at 1000g. Supernatant was removed and the pellet was resuspended in 500µL FACS 
buffer containing 1/1000 Hoechst and left at RT for ~20 mins before running on flow 
cytometry. A total of 50,000 events were collected. 
The PAC1 sample (described in 2.3.6) was centrifuged for two mins at 1000g and supernatant 
removed. The pellet was resuspended in 500µL FACS buffer and run on flow cytometry with 
a total of 50,000 events collected. 
 
2.3.9 Platelet Rich Plasma Assay 
The concentration of ATP released from platelet rich plasma (PRP) was determined using 
the Chrono-Log Model 700 Whole Blood /Optical Lume Aggregometer (Chrono-Log 
Corporation). The Chrono-Log measures ATP using a luminescent assay using firefly 
luciferin-luciferase (CHRONO-LUME reagent) as the ATP binds to the luciferin-luciferase 
and generates light. Briefly, 900µL (450µL PRP and 450µL saline) was transferred to 
cuvettes containing magnetic stir bars and allowed to pre-warm to 37ºC in the aggregometer 
wells for three minutes. 100µL CHRONO-LUME was added to each cuvette and incubated 
for two minutes before the addition of purified trophozoites (Section 2.3.4) or infected lysate 
(Section 2.3.5) and monitored for ATP release. 
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2.3.10 Gating strategy for positive events 
In order to measure percentage of positive events, flow cytometry was carried out using 
samples prepared as described in Section 2.3.6 with anti-PAC1 or anti-CD62P both 
conjugated to FITC (but different samples) and the following gating strategy was 
implemented (Figure 2.1). 
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Figure 2.1: Gating strategy for positive events. a) singlets gated using FSC-H vs FSC-A 
b) SSC-A vs FSC-A was used to gate for population of interest (POI) from a  c) unstained 
sample d) CD41 positive sample 
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2.4 Methods for Mouse Models of Thrombocytopenia  
All animal work was carried out in accordance with protocol A2014/55 at The Australian 
National University and housed under a 12 hour:12 hour light:dark cycle with food and water 
provided ad libitum. 
 
2.4.1 Blood collection from tail 
In order to measure platelet and RBC concentration, 5uL of blood was collected via pipette 
from each mouse through a small tail snip. Blood was added to 45uL of ACD buffer 
containing 0.01mg/mL anti-CD41-FITC (MWReg30, BD Biosciences) and 0.004mg/mL  
anti-TER-119-PeCy7 (TER-119, eBioscience). The blood/ACD mixture was incubated for 
30 mins at RT and 10µL was then added to 980µL PBS to subsequently run on flow 
cytometry. Before running the sample on flow cytometry, 10µL of 123ecounting beads 
(eBioscience) were added to the sample. 1000 bead events were collected to ensure 
statistically significant results. Using counting beads the concentration of platelets and RBCs 
were able to be back calculated using the following formula. 
Concentration of Platelets or RBCs/mL = (Events Collected/Bead volume (uL)*Dilution 
Factor*1000 
 
2.4.2 Giemsa smears: Mouse Blood 
In order to determine parasitaemia in mice, a drop of blood was collected from a tail snip and 
smeared. The slide was fixed in methanol for 45 secs and left to air dry and subsequently 
stained in Giemsa for 20 mins, before air-drying again, and visualizing under a light 
microscope.  
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2.4.3 Biotinylation of Cells 
When parasites were detected in the bloodstream via Giemsa staining (Section 2.4.2),  
200µL of PBS containing 1.5mg of EZ-Link Sulfo-NHS-LC-Biotin (ThermoFisher) was 
injected into the lateral vein of the mouse via intravenous (IV) injection. This labels all the 
cells of the blood, however for this assay biotinylated platelets were of interest. Four hours 
after IV injection, 5uL of blood was collected via a small tail snip. Blood was added to 45uL 
of ACD buffer containing. 5µL of blood/ACD mixture was subsequently added to 45µL 1x 
PBS containing 0.01mg/mL anti-CD41-FITC and 0.006mg/mL anti-TER-119-PeCy7 and 
0.01mg/mL streptavidin APC-Cy7 (eBioscience). The blood/ACD mixture was incubated 
for 30 mins at RT and added to 940µL PBS to subsequently run on flow cytometry. Before 
running the sample on flow cytometry, 10µL of counting beads was added to the sample, and 
1000 beads were collected to ensure statistically significant results.  
 
2.4.4 Gating Strategy for Platelets, Red Blood Cells, iRBCs and biotinylated platelets 
Using cell-specific markers, anti-CD41 for platelets, anti-TER-119 for RBCs, Hoechst for 
iRBCs and streptavidin for biotinylated platelets (Table 2.1), the following gating strategy 
was implemented (Figure 2.2) 
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Figure 2.2: Gating strategy for platelets/biotinylated platelets, RBCs and iRBCs. Gating 
strategy for platelets/biotinylated platelets, RBCs and iRBCs. a) beads were gated using a 
bead only control b) singlets gated using FSC-H vs FSC-A c) SSC-A vs FSC-A was used to 
gate for population excluding beads d) CD41-FITC vs TER-119-PeCy7 to distinguish 
platelet and RBC populations respectively e) platelet gate from d was used to measure 
populations double positive for biotin and CD41 and termed biotinylated platelets f) RBC 
gate from d was used to measure populations double positive for Hoechst and TER-119 and 
determined as an iRBCs.  
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2.4.5 Gating Strategy for Platelet Bound Red Blood Cells  
Using cell-specific markers, platelets bound to iRBCs and uRBCs were distinguished using 
the gating strategy described in Figure 2.3. 
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Figure 2.3: Gating strategy for platelet bound RBCs. a) beads were gated using a bead 
only control b) singlets and doublets gated using FSC-H vs FSC-A c) SSC-A vs FSC-A was 
used to gate for population excluding beads d) CD41 vs TER-119 to gate for all populations 
positive for TER-119 e) RBC gate from d was used to measure populations for TER-119+ 
and TER-119+ Hoechst + to gate uRBC and iRBCs respectively f) uRBC gate from e to gate 
for CD41+TER-119+ population representing platelet bound uRBCs g) iRBC gate from e to 
gate for CD41+TER-119+ population representing platelet bound iRBCs. 
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2.4.6 Statistical Analysis 
Statistical analysis was performed with GraphPad Prism 5 software using two-way-ANOVA 
or t-tests. P-values are listed in the legends of figures. Statistical significance was determined 
as P<0.05. 
Platelet consumption was examined using the biotinylated population, classified as the 
''original'' population at day of biotinylation. 50% (where y=50) of this biotinylated original 
platelet population was calculated using linear regression (Figure 2.4 shows an example) for 
each individual mouse. The mean from each group of mice (infected or uninfected) was used 
to determine the time taken for 50% clearance of biotinylated platelets.  
 
 
 
 
 
 
 
 
 
Figure 2.4 An example of a linear regression. Linear regression for one mouse, to find the 
time it took post-biotinylation for 50% of the original biotinylated platelets to remain in 
circulation. 
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Table of cell markers used for flow cytometry 
  
Table 2-1 Cell markers used to distinguish human and mouse populations of interest 
on flow cytometry 
 
 
. 
 
 
 
 
 
 
 
 
Parameter Measured Cell marker and fluorophore used 
Platelets (human) Anti-human PAC1-FITC (PAC1+)  
(PAC1, Biolegend) 
Anti-human CD62P-FITC (CD62P+)  
(AK4, BioLegend) 
Platelets (mouse) Anti-mouse CD41-FITC (CD41+) 
(MWReg30 BD Biosciences) 
Red Blood Cells (mouse) Anti-mouse TER-119-PeCy7 (TER-119+) 
(Ter-119 eBioscience) 
Infected Red Blood Cells (mouse) Anti-mouse TER-119-PeCy7 and Hoechst 
( TER-119+/ Hoechst +) 
Biotinylated Platelets (mouse) Anti-mouse CD41-FITC and Streptavadin-
APC-Cy7 (eBioscience) (CD41+/Biotin+) 
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Chapter 3 Platelet Activation in Response 
to Plasmodium falciparum 
 
Platelets have been found to play a protective role against infection by the malaria parasite 
P. falciparum by targeting its’ DV. PF4 has been implicated as the molecule responsible for 
the destruction of the parasite [69, 111], however the exact mechanism of how infected red 
blood cells (iRBCs) attract platelets and release PF4 is yet to be elucidated.  
 
It has been demonstrated that platelets can bind to iRBCs and uRBCs [70, 111] where, upon 
contact of platelets to iRBCs, PF4 is released by the platelet, and deposited onto the surface 
of the iRBC but not the uRBC [111]. After deposition onto the iRBC surface, PF4 is 
translocated to the DV and kills the parasite [69]. Platelets can interact with iRBCs via the 
platelet cell surface molecule CD36 binding to PfEMP1 variants translocated to the iRBC 
cell surface by the parasite [91]. However, the molecule(s) that parasites express resulting in 
PF4 release from platelets and subsequent deposition onto iRBCs, but not uRBCs, has yet to 
be determined. The aim of this chapter was to identify what molecule(s) the iRBC expresses 
to stimulate platelet secretion of PF4. Flow cytometry was used to measure platelet activation 
using the platelet markers anti-CD62P and anti-PAC1 (table 2.1). Purified trophozoite stage 
RBCsand lysed purified trophozoite stage RBCs (infected lysate) were used as agonists to 
investigate platelet activation. 
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Aims 
The aims of this chapter were: 
1. Confirm platelet activation using:  
1) Infected lysates from cultured cells at trophozoite stage by flow cytometry using 
anti-PAC1 and anti-CD62P as markers of activation. PF4 detection was carried out 
via ELISA. 
2) Intact RBCs at trophozoite stage using anti-PAC1 and anti-CD62P as platelet 
activation markers. PF4 detection was carried out via ELISA. 
2. Test for platelet activation using platelet:iRBC ratios to find the optimal 
concentration of molecule of interest to activate platelets.  
The above is described in more detail in Materials and Methods (Chapter 2). 
 
3.1 Platelet Activation Using Infected Lysate to Activate Platelets 
In order to identify the molecule(s) that iRBCs may express which activate platelets, infected 
lysates from cultured parasites were incubated with platelets and activation was quantified 
by flow cytometry. Briefly, RBCs infected with P. falciparum at ~5-10 % parasitaemia were 
purified using a Percoll gradient to obtain purified trophozoites (~80-90 %) (Section 2.3.4). 
Trophozoites were subsequently lysed using the hypotonic lysis method, as described in 
Section 2.3.5. Platelets at a concentration of 4.2x107platelets/mL were incubated with 
infected lysate (0.53mg/mL) for 45 mins at 37ºC. Activated platelets were quantified by flow 
cytometry using anti-PAC1 and anti-CD62P as markers of platelet activation. The assay was 
carried out three independent times in either duplicate or triplicate. 
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3.1.1 Platelet Activation Using Infected Lysate: anti-CD62P 
Results from three independent experiments carried out in either duplicate or triplicate using 
infected lysate from purified trophozoites are presented in Figure 3.1. Platelet activation was 
measured using anti-CD62P. Anti-CD62P is secreted from α-granules upon activation of 
platelets and is cell surface expressed. Platelets only and platelets that had been treated with 
hypotonic lysis buffer served as the negative control. 
Figure 3.1a shows that there was baseline activation of control, untreated platelets being 
positive for anti-CD62P (7% +/- 0.4%). When platelets were treated with thrombin which 
served as a positive control as it is a platelet agonist, there was almost 100% activation of 
platelets (96% +/- 1.0%) compared to buffer treated platelets (5.4% +/- 0.7%). When platelets 
were treated with infected lysate (6.7% +/- 0.6%), there was no significant difference 
between platelets that were treated with infected lysate, untreated platelets and buffer treated 
platelets. Mean fluorescent intensity (MFI) was also measured but no difference was seen in 
treatment groups except with thrombin treated platelets (23.1 +/- 0.4) (Figure 3.1b).  
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Figure 3.1 Activation of platelets using infected lysate: anti-CD62P. Positive events and 
mean fluorescent intensity was measured using flow cytometry using anti-CD62P as a 
marker of platelet activation. a) Percentage of positive events b) Mean fluorescent intensity. 
Thrombin was used as a positive control. Bars of graphs represent the mean of three 
independent experiments. Error bars indicate SEM ***P <0.05. 1way ANOVA using 
Tukey’s Multiple Compariston Test was used.  
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3.1.2 Platelet Activation Using Infected Lysate: anti-PAC1 
Another marker of platelet activation that was used was anti-PAC1. Anti-PAC1 recognizes 
an epitope on the glycoprotein IIb/IIIa (also known as CD41) complex of activated platelets 
located with, or near, the platelet fibrinogen-binding site [140]. Results from three 
independent experiments carried out in either duplicate or triplicate using infected lysate 
from purified trophozoites are presented in Figure 3.2. 
Figure 3.2a shows that compared to untreated platelets, treatment with thrombin resulted in 
increased expression of the anti-PAC1 marker, distinguished by both the number of 
positively stained platelets (96.5% +/- 0.7%), and the population MFI (93.0 +/- 12.1). 
Platelets treated with infected lysate also showed a significant increase in the percentage of 
positive events (79.0% +/- 2.8%) when compared to untreated platelets (18.0% +/- 1.7%), 
and buffer treated platelets (37.5% +/- 7.0%). This indicated that the infected lysate activated 
platelets and in turn exposed the integrin which resulted in increased levels of anti-PAC1 
being detected by flow cytometry. Mean MFI was also measured but no difference was seen 
in treatment groups except with thrombin treated platelets (Figure 3.2b). Taken together, 
these experiments indicated platelets were unable to be activated via the lysate of iRBCs as 
measured by anti-CD62P but possibly via anti-PAC1 as it may have been that the molecule 
acted on the glycoprotein IIb/IIIa causing activation and hence bind anti-PAC1 but not 
activate the alpha granule. 
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Figure 3.2 Activation of platelets using infected lysate: anti-PAC1. Positive events and 
mean fluorescent intensity was measured using flow cytometry using anti-PAC1 as a marker 
of platelet activation. a) Percentage of positive events b) Mean fluorescent intensity. 
Thrombin was used as a positive control. Bars of graphs represent mean of three experiments  
independent experiments. Error bars indicate SEM ***P<0.05. 1way ANOVA using Tukey’s 
Multiple Compariston Test was used.  
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3.1.3 Platelet Factor 4 Release Using Infected Lysate 
Another marker of platelet activation is PF4. PF4 is a chemokine secreted from the platelet 
alpha granule upon platelet activation. PF4 secretion by platelets in response to treatment 
with iRBC lysates was monitored using ELISA (Section 2.3.7) on the supernatant collected 
from the treated platelets. As seen in Figure 3.3, the supernatant from untreated platelets 
contained some PF4 (baseline level, approx. 1000 pg/mL). A significant increase in PF4 
concentration was seen when platelets were incubated with thrombin, consistent with the 
thrombin-mediated activation of platelets. This indicated that the platelets were able to be 
activated upon stimulation with an appropriate agonist. Platelets treated with hypotonic lysis 
buffer had no effect on platelet activation similar to the untreated control.  There was no 
difference observed between negative controls and infected lysate treated platelets. 
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Figure 3.3 Platelet Factor 4 ELISA with infected lysate. PF4 levels were measured using 
ELISA. Thrombin was used as a positive control. Bars of graphs represent mean of three 
independent experiments. Error bars indicate SEM. ***P <0.05. 1way ANOVA using 
Tukey’s Multiple Compariston Test was used.  
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3.1.4 Platelet Activation using Infected and Uninfected Lysate 
As shown in Figure 3.2a, infected lysate activated platelets. However, whether this was due 
to a parasite protein or an uRBC protein, was determined next. Figure 3.4a shows platelet 
activation using uninfected lysate. When uninfected lysate from control uRBCs was 
incubated with platelets to check activation levels, no platelet activation was observed 
between platelets treated with infected lysate or uninfected lysate (Figure 3.4a and Figure 
3.b). Thrombin did however activate platelets as shown by anti-PAC1 (88.1% +/- 0.6%) 
(Figure 3.4a) and anti-CD62P (56.5% +/- 3.3%) (Figure 3.4b), suggesting that this was not 
due to a lack of activation ability by the platelets.  MFI was again measured but no difference 
was seen, except with thrombin treated platelets via anti-PAC1 (27.8 +/- 0.8) (Figure 3.4c) 
and anti-CD62P (12.0 +/- 0.3) (Figure 3.4d). Even though no activation was observed with 
either infected or uninfected lysate, it is possible that the different batch of infected lysate 
used may have affected the lack of activation. This experiment was carried out once 
compared to three times previously (Figures 3.1 and 3.2) with a different preparation of lysate 
hence no definite conclusion can be made regarding activation of platelets using infected 
lysate. Hence, the next step was to determine if intact trophozoites activated platelets.  
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Figure 3.4 anti-CD62P and anti-PAC1 Positive events and mean fluorescent intensity. 
Positive events and mean fluorescent intensity was measured using flow cytometry using 
anti-PAC1 and anti-CD62P as a marker of platelet activation. a) anti-PAC1 positive events 
b) anti-CD62P positive events c) anti-PAC1 MFI D) anti-CD62P MFI. Thrombin was used 
as a positive control. Bars of graphs represent mean  of one independent experiment carried 
out in triplicate. Error bars indicate SEM, ***P<0.05 1way ANOVA using Tukey’s Multiple 
Compariston Test was used.  
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3.2 Platelet activation using purified trophozoite stage red blood cells 
To further investigate the inconsistent effects of parasitised cell lysates on platelet activation, 
additional studies were conducted examining the ability of RBCs at trophozoite stageto 
activate platelets using the same three markers of platelet activation. It was hypothesized that 
intact trophozoites may express a protein(s), which when expressed appropriately on the cell 
surface, are responsible for platelet:iRBC contact and subsequent platelet activation. In 
addition, it has previously been shown, using PRP incubated with purified iRBC membranes, 
that platelets were able to be activated using anti-PAC1 as a marker [100]. 
 
3.2.1 Platelet Activation Using Purified Trophozoite stage: anti-CD62P and anti-PAC1 
Infected RBCs at trophozoite stage were purified via a Percoll gradient which yielded 
approximately 80-90% trophozoites (Section 2.3.4). Initial trophozoite-platelet incubations 
were conducted using 1:10 platelet to trophozoite ratio. Using anti-CD62P and anti-PAC1, 
the percentage of positive events were measured using flow cytometry. Infected RBCs at 
trophozoite stage RBCs did not activate platelets when anti-CD62P was used as a marker as 
there was no difference between trophozoite treated platelets (6.1% +/- 0.6%) and uRBC 
treated platelets (5.3% +/- 1.5%). There was a significant difference in thrombin treated 
platelets (58.8% +/- 4.7%) compared to untreated platelets (11.1% +/- 3.7%) indicating that 
platelets were able to be activated upon stimulation with an appropriate agonist (Figure 3.5a). 
MFI was measured but no difference was observed except with thrombin treated platelets 
(Figure 3.5c) (22.2 +/- 3.0). Using anti-PAC1 as a marker for platelet activation, no platelet 
activation was seen using trophozoite stage parasites (3.1% +/- 1.3%) compared to uRBC 
treated platelets (3.4% +/- 1.5%) (Figure 3.5b). MFI was unable to be analyzed due to data 
not saved in the correct format for CD62P.  
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Figure 3.5 Platelet activation by RBCs at trophozoite stage. Positive events and mean 
fluorescent intensity was measured using flow cytometry using anti-PAC1 and anti-CD62P 
as a marker of platelet activation. a) anti-PAC1 positive events b) anti-CD62P positive events 
c) anti-PAC1 MFI. Thrombin was used as a positive control. Bars of graphs represent mean 
of two independent experiments. Error bars represent SEM. ***P <0.05. 1way ANOVA 
using Tukey’s Multiple Compariston Test was used.  
 
3.2.2 Platelet Factor 4 Release Using purified trophozoite stage red blood cells: anti-
PAC1 and anti-CD62P 
Another set of trophozoite stage RBC-platelet incubation experiments were performed using 
various cell ratios starting from a 1:1 platelet to trophozoite ratio. This experiment included 
additional controls of platelets incubated with uRBCs at the same ratios, as well as thrombin 
as a positive control. All of platelet:trophozoite ratio supernatants were assayed for PF4 
concentrations. Figure 3.6 shows, there was baseline activation as seen by PF4 release in 
untreated and media treated platelets. Thrombin was able to cause PF4 secretion, albeit at a 
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lower level to that which was previously observed, which may suggest the platelets were not 
functioning normally; however the experiment was carried out two independent times in 
triplicate each time with different platelet donors. Neither trophozoite stage RBCs nor 
uninfected RBCs caused PF4 secretion. At the ratio of 1:0.0625, although significant (P 
0.008) there was no significant difference between the platelet:trophozoite ratio and media 
(p 0.1066) which acted as a control. 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Platelet Factor 4 ELISA with trophozoite stage RBCs a) a significant 
difference was seen in PF4 when thrombin was incubated with platelets. PF4 was measured 
in trophozoite treated platelets at various ratios. Bars of graphs represent mean of two 
independent experiments *** p <0.001. 
Statistics was carried out on GenStat using two-way ANOVA.  
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Discussion 
Platelets have been shown to play a role in the killing of the malaria parasite by targeting the 
(DV [69]. It has been shown that PF4, in conjunction with the Duffy receptor on RBCs, 
targets the DV, lysing it and killing the parasite [111]. Platelets can bind to iRBCs, however 
it is only when a platelet adheres to an iRBC that PF4 is secreted [111]. The molecule(s) an 
iRBC expresses or secretes that ensures only a platelet bound to an iRBC secretes PF4 has 
yet to be determined and was the main aim of this chapter.  
 
This study used three markers of platelet activation; anti-CD62P, PF4, and anti-PAC1.  
Anti-CD62P [141] and PF4 [142] are released from α-granules upon platelet activation, 
whilst anti-PAC1 recognizes an epitope on the glycoprotein IIb/IIIa (also known as CD41) 
complex of activated platelets located with, or near, the platelet fibrinogen-binding site 
[140]. 
In order to measure platelet activation, flow cytometry was used with the use of two 
parameters; percent of positive events and mean fluorescent intensity (MFI). MFI is 
the mean of the fluorescent intensity in the fluorescence channel in use, whilst percent of 
positive events is the number of cells that have bound antibodies of interest to it. However, 
sometimes using positive events is a more precise way of interpreting FACS data. This is 
due to MFI being a mean of intensity – such that it depends on the amount of antibody 
attached to a certain population of cells and assuming that the antibody is evenly distributed 
across the cell population of interest. In the above experiments, the percent of positive events 
and MFI were used using the platelet activation markers anti-PAC1 and anti-CD62P. PF4 
detection was carried out via a commercially available PF4 ELISA kit. 
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The first aim of the project was to observe platelet activation via the addition of infected 
lysate. RBCs at trophozoite stage were lysed hypotonically which was subsequently termed 
“infected lysate” and incubated with purified human platelets. This was conducted to narrow 
down the potential parasite expressed molecule(s) responsible for platelets solely binding to 
iRBCs and subsequent deposition of PF4 on to the surface (i.e if a cytoplasmic protein was 
responsible). Using one batch of infected lysate, a consistent activation of platelet 
glycoprotein IIb/IIIa receptor (PAC1) was observed, but not alpha granule activation. 
However, using second lysate preparation no activation through either pathway was 
observed. 
 
It must be noted that two batches of purified lysate were used. The first batch was used for 
the three experiments (Figure 3.2a) which showed that whole protein caused activation. The 
second batch of protein however showed that no activation occurred (Figure 3.4a). After 
purification for both lysates, Giemsa smears indicated ~80-90% trophozoite stage parasites 
were present. Although unlikely, it may be possible that the first batch of infected lysate that 
was used expressed a parasite protein in a given point in time in which the second batch of 
parasites did not, thus contributing to the differences in platelet activation observed between 
experiments.  
Due to the lack of reproducibility no conclusive statement was able to be made regarding the 
activation of platelets via parasites. 
  
It has been previously shown using flow cytometry, with anti-PAC1 as markers of platelet 
activation, that when PRP was incubated with Percoll purified intact trophozoite stage 
iRBCs, there was a significant increase in MFI for anti-PAC1 [100]. PF4 levels were also 
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measured and showed a significant difference in PRP treated with iRBCs compared to PRP 
control uRBCSs. Another study also showed PF4 release in the presence of human purified 
platelets [111]. In order to determine what molecule(s) the iRBC expressed was responsible 
for activating platelets, Srivastava and colleagues [100] incubated PRP with saponin purified 
P. falciparum or hemozoin. Pure trophozoites did not stimulate platelets, nor did purified 
hemozoin. Purified membranes of iRBC did however activate platelets whilst uRBC 
membranes did not which demonstrated that Plasmodium iRBCs express membrane proteins 
that are pro-thrombotic [100]. 
In this thesis, Percoll purified intact trophozoite stage RBCs were incubated with human 
purified platelets using the same markers as the previously published data; anti-CD62P and 
anti-PAC1. However, platelet activation was not observed. PF4 detection was also measured 
via ELISAs after human purified platelets were incubated with Percoll purified intact 
trophozoite stage RBCs but no PF4 was detected. 
 
A difference in the designs of the studies must be noted. In the current study, activation of 
platelets was carried out using purified platelets and not PRP as the study conducted by 
Srivastava and colleagues [100]. Although PRP has a high concentration of platelets it 
contains other components such as chemokines, cytokines, growth factors, adhesive proteins 
and proteases [143]. It may be possible that another component in PRP may work together 
with iRBCs to activate platelets which is likely to occur in an in vivo setting.  
 
To parallel the PRP experiment, the CHRONO LOG® Model 700 Whole Blood/Optical 
Lumi-Aggregometer was used to measure Adenosine 5'-triphosphate (ATP) release from 
dense granules of activated platelets. Activated platelets release ATP from their dense 
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granules [144] and the Chronolog is based on the luciferin-luciferase assay which binds ATP, 
generating light which is proportional to the amount of ATP released by the platelets when 
stimulated with an appropriate agonist .  
In this chapter, PRP incubated with thrombin was used as a positive control and had a ATP 
reading of >0.5nm which fell into the expected range. When intact purified trophozoites were 
incubated with PRP, no ATP was released indicating that purified RBCs at trophozoite stage 
were unable to activate PRP, which further strengthens the previous experiment by flow 
cytometry where purified human platelets in the presence of intact trophozoites were not 
activated. 
A contributing factor to the lack of platelet activation observed could be the time between 
Percoll purification and subsequent use of parasites in the platelet assay. Purified RBCs at 
trophozoite stage were used shortly after purification although it may be possible that the 
time between purifying and use in the assay was too long thus making the parasites no longer 
viable and therefore the molecule(s) of interest unable to activate platelets. 
A number of attempts and protocol variations were carried out to test if Plasmodium iRBCs 
can cause platelet activation. Whole protein lysate from trophozoite stage infected cells was 
observed to activate platelets based on the anti-PAC1 marker. However, subsequent parasite 
preparations, including other lysate preparations and intact parasitised cells produced 
inconsistent effects and generally no activity against platelets. It remains unclear whether 
this was due to technical reasons, variations in the parasite strain as various cultures were 
used over the course of these trials (more than 12 months), or other unknown reasons.   
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Chapter 4 Thrombocytopenia in Mouse 
Models of Plasmodium chabaudi 
 
It was reported as far back as 1924 that platelet numbers were reduced in the peripheral blood 
of patients with acute malaria [145]. This decrease in platelet number is termed 
'thrombocytopenia', with clinical thrombocytopenia cited in the literature as  platelet 
concentration less than <150,000/mm3 [146]. During a malaria infection, up to 80% of 
patients have thrombocytopenia, with a distinct negative correlation between platelet 
concentration and parasitaemia. The causes of malaria-induced thrombocytopenia are wide 
and varied, and not well understood, but platelet consumption or destruction is thought to 
play a vital role [147]. Other possible mechanisms that have been proposed include splenic 
pooling, liver sequestration and endothelial activation. 
 
It has been previously shown in human [124], mouse [70] and monkey [125] models of 
malaria that a loss of platelets accompanies an increase in parasitaemia. In a study conducted 
in the McMorran lab, thrombocytopenia was investigated in a cohort of mice infected with 
Plasmodium chabaudi. Whilst thrombocytopenia was observed it was also  noted here that 
platelets may bind preferentially to infected iRBCs over uRBCs [70].  
Whilst cohorts of mice were sacrificed in that study [70], the present mouse model used to 
measure platelet concentration levels was based on Alugupalli and colleagues [148]. When 
compared to human malaria infections such as that by de Mast and colleagues, both models 
show that thrombocytopenia occurs before the onset of symptoms such as anaemia, therefore 
showing platelet loss is a good indicator of a suspected malarial infection. The mouse model 
used shows that although platelet concentration returns to normal they usually die as a result 
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of anaemia whilst human studies show that with anti-malarials, platelet concentrations also 
return to normal [149].  
The research reported in this chapter builds upon previous mouse malaria studies and 
describes the relationship between platelet bound iRBCs and platelet bound uRBCs in 
thrombocytopenia. 
 
The aims of this chapter were to 
1. Develop protocols to quantify platelet, parasite and platelet-RBC complex 
concentrations in mice on a daily basis, and determine the time taken of platelet 
clearance in mice infected with P. chabaudi to occur. 
2. Investigate the relationship between the concentration of unbound platelets and 
platelet complexes and assess the contribution of complexes towards the loss of 
platelets in malaria-induced thrombocytopenia.  
3. Determine if platelet loss was a result of inhibition of platelet production or due to 
platelet consumption, by measuring the time for platelet clearance to occur during the 
course of infection 
 
In order to address these aims, experiments were first conducted to develop a protocol to 
allow continuous monitoring of parasite, platelet, RBC and platelet-RBC complexes using 
flow cytometry to observe and quantify thrombocytopenia and platelet-RBC complex 
formation over the course of an infection in the same mice. This allowed confounding factors 
such as inter/intra-mouse variation to be monitored. Several pilot experiments were 
conducted to optimise the daily collection of blood samples from the tail, as well as 
optimising the use of flow cytometry with counting beads and antibodies specific for platelets 
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and RBCs (refer to Section 2.4.1 and 2.4.3) section for the optimised protocol). To measure 
the rates of platelet clearance a protocol was developed using IV injected EZ-Link NHS-
Biotin (biotin) to label all circulating cells and quantify the relative proportions of biotin-
labelled and unlabeled platelets over time. This involved optimising the volumes of blood 
and concentrations of streptavidin-fluorophore conjugate to efficiently label all biotinylated 
cells in the samples.  
Male mice were infected with 1x105 parasites (P. chabaudi) and during the course of 
infection, platelet, RBC, iRBC concentrations, and frequencies of uRBC and iRBC bound to 
platelets were measured (plt:uRBC and plt:iRBC respectively). Three separate infection 
experiments were conducted, consisting of between three and seven infected mice as well as 
between three and nine uninfected controls. The first experiment was conducted to observe 
thrombocytopenia whilst in the other two experiments, infected animals were IV injected 
with biotin when parasite levels were between 1% & 3% to monitor clearance of circulating 
platelets. RBCs were measured using the RBC cell surface marker TER-119 antibody which 
recognizes a molecule associated with glycophorin A and marks all stages of murine RBCs. 
Platelets were measured using anti-CD41 as CD41 is a glycoprotein expressed by platelets. 
To measure infected RBCs, Hoechst dye (which stains DNA, of which mature RBCs have 
none) and anti-TER-119 were used. Table 2.1 provides a summary of the markers used and 
the parameters each measured.  
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4.1 Challenge #1: Platelets, Red Blood Cells and Platelet Complexes during a 
Plasmodium chabaudi infection in male mice  
The major aim of this challenge was to confirm that the optimized platelet, RBC and parasite 
quantification protocol could be used to successfully observe malaria-induced 
thrombocytopenia and the formation of platelet-RBC complexes. A total of eight mice were 
investigated, five uninfected and five infected with 1x105 P. chabaudi parasites via 
intraperitoneal (IP) injection. Of the infected, only three mice had detectable parasites in their 
bloodstream. 
The development of parasitaemia was monitored in the infected mice by Giemsa staining as 
described in section 2.4.2. Blood samples for platelet and RBC quantification were collected 
each day beginning seven days post-infection, and sampling continued until the infections 
had resolved (Figure 4.1a). Quantifiable levels of parasites were observed between days ten 
and 17 following infection, and peak parasitaemia occurred on day 13 (30% +/- 6.2%). 
Measured platelet concentrations in the uninfected mice were relatively stable for the first 
two days of sampling although they were approximately 70% of the levels expected for this 
strain. There was an unusual spike in platelet numbers measured on day nine (for both 
infected and uninfected groups) that was probably due to unidentifiable technical reasons or 
perhaps a FACS calibration error rather that representing a true physiological change. Platelet 
concentrations in the infected mice were the same as the uninfected mice between days 
seven-ten, and then began decreasing markedly on day 11. Levels reached a nadir on day 13  
(4.7x107 +/- 5.5x106cells/mL) and began increasing and reached the same levels as the 
uninfected group on day 16. The lower levels of platelets in the infected group were 
statistically significant on days 12-15.  
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RBC concentration was also measured using flow cytometry (Figure 4.1b). From the first 
three days of sampling (days seven-nine), uninfected mice had relatively consistent RBC 
concentrations although this was 70% of what was expected for C57BL/6 mice 
(1.0x1010cells/mL). By the fourth day (day ten post-infection) of sampling, RBC 
concentrations dropped by 15% (5.7x109 +/- 5.5x109cells/mL) of the original RBC 
concentration and continued to decline until the end of the experiment. The first five days 
decreased slowly and thereafter, a large decrease was seen by the end of experiment where 
RBC concentration was 3.6x109 +/- 8.8x108cells/mL. There was a spike in RBC 
concentrations on day 15 possibly due to a technical rather than biological reason. This 
decrease in RBC concentration may have been a result of daily sampling and therefore mild 
anaemia may be occurring as a result of lost RBCs. In infected mice, days seven and eight 
had consistent RBC concentrations whilst on day nine the spike in RBCs may have been due 
to technical reasons rather than biological. Although from day nine there is a decrease in 
RBC concentrations a significant difference is only observed between infected and 
uninfected mice RBC concentrations on day 14 and 15. RBC concentration reached a nadir 
on days 15 and started to increase to uninfected concentrations thereafter. One mouse died 
on day 15 which was most likely due to anaemia and all remaining mice recovered with 
decreasing parasite load. 
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Figure 4.1 Platelet and RBC concentration compared to parasitaemia in male C57BL/6 
mice. 5 µL blood was collected from infected mice (3) and uninfected mice (5), mixed with 
ACD and labeled with anti-TER-119 and anti-CD41 to measure RBC and platelets 
respectively. Y-axis indicates cells/mL and X-axis indicates day post parasite infection. a) 
Platelet concentration compared to parasitaemia – platelet levels reached a nadir on day 13 
b) RBC concentrations compared to parasitaemia – RBC levels reached a nadir on day 15. 
Error bars depict SEM.  *p <0.05, **p <0.01, ***p <0.001. Red box indicates expected 
values from published data. 2way ANOVA was used to measure differences between 
infected and uninfected mice on various days.  
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4.1.1 Preferential Binding of Platelets to Red Blood Cells During a Malaria Infection 
The percent of platelets bound to iRBCs and uRBCs is shown in Figure 4.2a. Platelet binding 
to RBCs in uninfected mice remained stable throughout the course of infection (~0.4%) and 
there was no difference between platelets bound to uRBCs in infected mice compared to 
uninfected mice. This shows that growth of parasites in the bloodstream and the platelet loss 
does not apparently affect the frequency of the platelets bound to uRBCs during infection. In 
infected mice, plt:iRBC complexes were first observed and quantifiable on Day 11. There 
was a significantly greater difference between platelet binding to iRBCs compared to uRBCs 
on days 11 and 17. On day 11, platelet binding was 7-fold higher to iRBCs compared to 
uRBCs. On day 17, platelet binding was 11-fold higher to iRBCs compared to uninfected 
RBCs.  
The days on which preferential binding was observed coincided with the times when parasite 
levels were high enough to be quantified and platelet numbers had not yet reached a nadir 
(day 11), or had recovered (day 17). Therefore, the ability to observe preferential binding 
may depend on there being sufficient numbers of parasites and platelets in the circulation. 
Figure 4.2b describes the relationship between parasitaemia, platelet concentration and 
plt:iRBC binding in infected mice where days 11 and 17 show preferential binding when 
platelet concentration is still high and parasitaemia is quantifiable for the first time. 
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Figure 4.2 Relationship between platelet binding to iRBC and uRBCs in male C57BL/6 
mice. Flow cytometry was used to measure platelet bound RBC populations from infected 
mice (3) using anti-TER-119 and Hoechst to distinguish iRBCs from uRBCs, and anti-CD41 
for platelets. a) The percentage of platelets bound to RBCs is shown for each day post-
infection. b) Relationship between parasitaemia, platelet concentration and plt:iRBC binding 
a 
 
a 
b
 
 
a 
 
a 
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in infected mice. Error bars represent SEM. **p <0.01, ***p < 0.005 2way ANOVA was 
carried out to determine differences in platelet binding. 
 
4.2 Challenge 2: Platelet Clearance in Male Mice  
A preliminary study consisting of a small cohort of mice was used in the next malaria 
infection to measure the clearance of platelets during a malarial infection. To determine 
clearance of platelets during a P. chabaudi infection, biotin was used to label all cells in the 
blood including platelets by IV injection to track the original platelets in circulation over the 
course of infection along with newly produced platelets which would therefore not be 
biotinylated. This allowed us to determine whether thrombocytopenia was a result of platelet 
consumption or inhibition of platelet production by measuring the proportion of biotinylated 
and nonbiotinylated platelets. 
 
4.2.1 Platelet and Red Blood Cell Concentration during a Plasmodium chabaudi 
infection in male mice  
During this challenge parasites were much more virulent than previous challenges, with 
parasitaemia reaching approximately 80% resulting in all mice dying by the end of challenge. 
Measured platelet concentrations in the uninfected mice were at expected levels of C57BL/6 
mice on the first two days of sampling (1x109cells/mL). There was an unusual decrease in 
platelet numbers measured on day eight, probably due to unidentifiable technical reasons 
rather that representing a true physiological change. For the rest of the infection, platelet 
concentrations remained at expected levels. Platelet concentration in infected mice were at 
similar levels pre-infection and not significant compared to uninfected mice platelet 
concentrations for the first two days of sampling. Platelet concentration between infected and 
uninfected mice were significantly different on days 9-12. Due to the unidentifiable decrease 
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in platelet concentrations on day eight, due to an error, in infected mice, it is not possible to 
tell if there was no significant difference in platelet concentrations that day. 
RBC concentration was also measured using flow cytometry. RBC concentrations in 
uninfected mice were approximately 50% of the expected value for C57BL/6 mice and stayed 
relatively consistent throughout the course of infection. The fluctuations in RBC 
concentration in infected mice make it difficult to determine direct differences, although 
anaemia is clearly observed on days 11-12 of infection suggesting that all mice died of 
anaemia. 
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Figure 4.3 Platelet and RBC concentration compared to parasitaemia in male C57BL/6 
mice. 5 µL blood was collected from infected mice (5) and uninfected mice (3), mixed with 
ACD and labeled with anti-TER-119 and anti-CD41 to measure RBC and platelets 
respectively. Y-axis indicates cells/mL and X-axis indicates day post parasite infection. a) 
Platelet concentration compared to parasitaemia b) RBC concentrations compared to 
parasitaemia. Error bars depict SEM.  ***p <0.001. Red box indicates expected values from 
published data. 2way ANOVA was used to measure differences between infected and 
uninfected mice on various days. 
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4.2.2 Platelet Clearance During a Plasmodium chabaudi Infection in Male Mice  
To determine if platelet clearance was affected during a malaria infection, biotin was injected 
into the lateral vein of the mouse tail via IV injection when parasites were detected in the 
bloodstream. Blood was sampled approximately four hours after IV injection on the day of 
biotinylation, and initial percentage of biotinylated platelets designated as 100%. 
Biotinylated platelets were gated as CD41+Biotin+ (Section 2.4.4) by flow cytometry. 
Samples were taken approximately every 24 hours to measure biotinylated and non-
biotinylated platelets over the course of infection.  
The time taken for 50% of the original population of biotinylated platelets to be cleared was 
calculated using linear regression on GraphPad Prism as described in section 2.4.6. There 
was a significantly shorter time of platelet consumption in infected mice (1.6 +/- 0.02 days) 
compared to uninfected mice (2.3 +/- 0.1 days) to reach 50%, indicating platelet consumption 
was playing a role in malaria-induced thrombocytopenia. However, whether the inhibition 
of platelet production was a factor was uncertain, and so, was addressed next. 
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Figure 4.4 Clearance of biotinylated platelets. A 1/2000 dilution of blood was labeled with  
anti-CD41 and streptavidin to measure the percentage of biotinylated platelets in infected 
mice (5) and uninfected mice (3) using flow cytometry. Error bars represent SEM. Arrows 
indicate day post-biotinylation where 50% biotinylated platelets remain in circulation. Red 
(infected) and blue (uninfected). *p 0.0357 Linear regression was used to calculate the 
difference between biotinylated platelets in infected and uninfected mice. 
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4.2.3 Platelet Consumption or Inhibition of Production 
The concentration of biotinylated and nonbiotinylated platelets over the course of infection 
is shown in Figure 4.5. On the day of biotinylation, there was no significant difference in the 
concentration of biotinylated platelets and nonbiotinylated platelets between infected and 
uninfected mice.  
Due to a possible artefact/experimental error, the platelet concentration on the day of 
biotinylation is much lower than expected, however on subsequent days platelet 
measurements were of expected numbers. 
On days one-three post biotinylation, there was a significant difference in biotinylated 
platelets between infected and uninfected mice. There was a significant difference between 
day one-four post biotinylation in the concentration of non-biotinylated platelets between 
infected and infected mice, which suggests that platelet consumption but also possibly an 
inhibition of platelet production plays a role in malaria induced thrombocytopenia. 
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Figure 4.5 Biotinylated and nonbiotinylated platelets in infected and uninfected mice 
over the course of infection. Biotin was injected at 1.5mg into the lateral vein of infected 
mice (5) and uninfected mice (3) and samples collected on the day of biotinylation and 24 
hours later on subsequent days in order to measure the proportion of biotinylated (red) and 
nonbiotinylated (blue) platelets in infected (shaded) and uninfected mice (unshaded) over the 
course of infection. Error bars represent SEM. **p <0.01, ***p <0.001. 2way ANOVA was 
carried out to measure differences between infected and uninfected mice. Red statistical lines 
are comparing differences between biotinylated platelets in infected and uninfected mice. 
Blue statistical lines are comparing differences between nonbiotinylated platelets in infected 
and uninfected mice. 
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4.2.4 Preferential Binding of Platelets to Red Blood Cells 
The percent of platelets which were bound to iRBCs and uRBCs is shown in Figure 4.6a. 
Platelet binding to RBCs in uninfected mice was not significantly different throughout the 
duration of infection. There was no difference between platelets bound to uRBCs in infected 
mice compared to uninfected mice. In infected mice plt:iRBC complexes were first observed 
and quantifiable on day eight. There was a significantly greater difference between platelets 
binding to iRBCs compared to uRBCs only on day eight. On day eight platelet binding was 
3.5-fold higher to iRBCs compared to uninfected RBCs.  
The day on which preferential binding was observed (day eight) coincides again with the 
times when parasites levels were again high enough to be quantified and platelet 
concentrations were not yet significantly different between infected and uninfected mice. 
4.6b describes the relationship between parasitaemia, platelet concentration and plt:iRBC 
binding in infected mice where on day eight preferential binding is observed when platelet 
concentration is still high and parasitaemia is quantifiable for the first time. 
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Figure 4.6 Relationship between platelet binding to iRBC and uRBCs in male C57BL/6 
mice. Flow cytometry was used to measure platelet bound RBC populations using anti-TER-
119 and Hoechst to distinguish iRBCs from uRBCs and anti-CD41 for platelets in infected 
mice (5).  a) The percentage of platelets bound to RBCs is shown for each day post-infection. 
b) Relationship between free platelets, plt:iRBCs and parasitaemia in infected mice. Error 
bars represent SEM. **p <0.01 2way ANOVA was carried out to determine differences in 
platelet binding. 
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4.2.5 Rate of Loss of Free Platelets vs Platelet Bound Red Blood Cells 
In order to determine the proportion of platelets bound to iRBC and uRBCs contributing to 
thrombocytopenia in infected mice, the total unbound platelets and total biotinylated platelets 
verses plt:iRBCs and plt:uRBCs were compared in Figure 4.7. The contribution complexes 
have in proportion to total platelets (platelet bound iRBCs + platelet bound uRBCs + 
biotinylated + nonbiotinylated platelets) was 3.6% on the day of biotinylation, 3.4% day one, 
3.3% day two, 2.1% day three, and 2.6% on day four post biotinylation. However, due to the 
inability to distinguish what part of the complex is biotinylated (the platelet or RBC since IV 
biotinylation in vivo stains all blood cell types) the concentration of complexes cannot 
accurately determine newly formed complexes or platelets which may have become detached 
over the course of infection. The concentration of free biotinylated platelets decreases over 
the duration of infection whilst the total platelet pool also decreases but takes into the account 
newly synthesized platelets.  
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Figure 4.7 Preferential binding of platelets to infected and uninfected cells vs free 
platelets. Concentration total platelets (blue), free biotinylated platelets (black), plt:iRBC 
(red) and plt:uRBC (green) in five infected mice was measured via flow cytometry. Total 
platelets include plt:iRBC/plt:uRBC/biotinylated platelets and nonbiotinylated platelets. Red 
arrow indicates time when 50% biotinylated platelets remain. Error bars represent SEM.  
**p <0.01 
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4.3 Challenge #3: Platelet Clearance in Male Mice  
The previous experiment was used as a preliminary study and as such had a low number of 
mice in both the infected and uninfected groups. The last malaria infection of this chapter, 
had a larger cohort of mice to increase the statistical power. 
 
4.3.1 Platelet and Red Blood Cell Concentration During a Plasmodium chabaudi 
Infection in Male Mice  
A total of 16 mice (seven infected and nine uninfected) were used in the last challenge of this 
chapter. 1x105 P. chabaudi parasites were injected by IP into mice, and platelet, RBC and 
iRBC concentrations were measured using flow cytometry. The markers used to investigate 
this were anti-CD41, anti-TER-119 and Hoechst respectively. Parasitaemia was verified with 
Giemsa stained slides and parasites were first detected in the bloodstream from day ten until 
the end of challenge on day 17, with peak parasitaemia reached on day 14 (53.8 +/- 10.4%). 
Three mice died by the end of the challenge. 
Figure 4.8a shows platelet concentrations and the corresponding parasitaemia in male 
C57BL/6 mice infected with P. chabaudi over the course of infection.  
Platelet concentrations in uninfected mice were at the expected levels and were stable 
throughout the infection (1x109cells/mL). Platelet concentrations in infected mice were 
similar to uninfected mice concentrations pre-infection and days one to nine, then started to 
decrease markedly from day ten. Platelet concentration reached a nadir on day 13 in infected 
mice and started thereafter to increase.  
There was a significant difference in platelet concentrations between infected and uninfected 
mice between days 11-15. 
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RBC concentration was also measured using flow cytometry. In uninfected mice, 
concentrations were at approximately 60% of expected levels of C57BL/6 mice at the start 
of infection but fluctuated on a daily basis, although there appears to be anaemia by the end 
of the challenge as RBC concentration by day 17 had dropped by 40% compared to the 
starting concentration. Infected mice RBCs were similar to uninfected concentrations for the 
first two days of sampling, then spiked (day seven), most likely due to technical aspects 
rather than biological. RBC concentrations for the next four days fluctuate, however there is 
a clear decrease in RBC concentration from day 12 onwards with a significant difference 
between iRBC and uRBC concentrations on day 16, although due to the fluctuating nature 
of concentrations it is difficult to make a definite comparison on this day.   
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Figure 4.8 Platelet and RBC concentration compared to parasitaemia in male C57BL/6 
mice. Nine uninfected mice were used as control mice whilst seven mice were infected with 
1x105 parasites and samples collected daily and measured on flow cytometry. a) Platelet 
concentration over the course of infection with parasitaemia curve. b) RBC concentrations 
over the course of infection with parasitaemia curve. Error bars depict SEM.  *p <0.05, ** p 
< 0.01 ***p <0.001. Red box indicates published values. 2way ANOVA was used to measure 
differences between infected and uninfected mice on various days. 
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4.3.2 Platelet Clearance During a Plasmodium chabaudi Infection in Male Mice  
To determine if platelet clearance was affected during a malaria infection, biotin was injected 
into the lateral vein of the mouse tail by IV when parasites were detected in the bloodstream. 
Blood was sampled approximately four hours after IV injection on the day of biotinylation, 
and initial percentage of biotinylated platelets designated as 100%. Biotinylated platelets 
were gated as CD41+Biotin+ by flow cytometry. Samples were taken approximately every 24 
hours to measure biotinylated and non-biotinylated platelets over the course of infection.  
The time taken for 50% of the original population of biotinylated platelets to be cleared was 
calculated by using linear regression on GraphPad Prism as described in section 2.4.6.  There 
was a significantly shorter time in infected mice (1.5 +/- 0.05 days) compared to uninfected 
mice  
(2.1 +/- 0.1 days) to reach 50% of original platelet levels, indicating platelet consumption is 
playing a role in malaria-induced thrombocytopenia. However the inhibition of platelet 
production was again addressed in the next Section 4.3.3.  
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Figure 4.9 Clearance of biotinylated platelets. Biotin was injected into the lateral tail vein of five 
infected mice and four uninfected mice. Blood samples were collected on the day of biotinylation and 
four consecutive days thereafter. Percent of biotinylated platelets was measured via flow cytometry. 
Arrows indicate day post-biotinylation where 50% biotinylated platelets remain in 
circulation. Red (infected) and blue (uninfected). Error bars represent SEM. P 0.0159. Linear 
regression was used to calculate the difference between biotinylated platelets in infected and 
uninfected mice. 
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4.3.3 Platelet Consumption or Inhibition of Production 
The concentration of biotinylated and nonbiotinylated platelets over the course of infection.is 
shown in Figure 4.10. From the day of biotinylation and the next two days, there was a 
significant difference in the remaining concentration of biotinylated platelets between 
infected and uninfected mice. From days three to six post biotinylation, there was also a 
significant difference in the concentration of nonbiotinylated platelets between infected and 
uninfected mice suggesting that platelet production may also possibly be playing a role. 
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Figure 4.10 Biotinylated and nonbiotinylated platelets in infected and uninfected mice 
during infection. Concentration of biotinylated and nonbiotinylated during infection in 
infected mice (5) and uninfected mice (4). Error bars represent SEM. ***p <0.001. 2way 
ANOVA was carried out to measure differences between infected and uninfected mice. 
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4.3.4 Preferential Binding of Platelets 
The percent of platelets bound to iRBCs and uRBCs is shown in Figure 4.11a. Platelet 
binding to RBCs in uninfected mice was not significantly different throughout the duration 
of infection. There was no difference between platelets bound to uRBCs in infected mice 
compared to uninfected mice. In infected mice plt:iRBC complexes were first observed and 
quantifiable on day ten. There was a significantly greater difference between platelet binding 
to iRBCs compared to uRBCs only on day ten. On day ten platelet binding was 2.3-fold 
higher in iRBCs compared to uRBCs.  
The day on which preferential binding was observed (day ten) coincides again with the times 
when parasites levels were high enough to be quantified and platelet concentrations were not 
yet significantly different between infected and uninfected mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
90 
 
9 10 11 12 13 14 15 16 17
0.0
5.0×1008
1.0×1009
1.5×1009
0
20
40
60
Plt:iRBC (infected mice)
Platelets (infected)
Parasitaemia
Day post infection
p
la
te
le
ts
/m
l
%
 p
a
ra
s
ita
e
m
ia
 a
n
d
 (p
lt:iR
B
C
s
 x
 1
0
)
9 10 11 12 13 14 15 16 17
0.0
0.5
1.0
1.5
2.0
2.5
plt:iRBC (infected mice)
plt:uRBC (infected mice)
plt:uRBC (uninfected mice)
***
Day post infection
%
 b
in
d
in
g
 p
la
te
le
ts
 t
o
 R
B
C
s
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Relationship between platelet binding to iRBC and uRBCs in male 
C57BL/6 mice. Flow cytometry was used to measure platelet bound RBC populations using 
anti-TER-119 and Hoechst to distinguish iRBCs from uRBCs, and CD41 for platelets in 
infected mice (5).  a) The percentage of platelets bound to RBCs is shown for each day post-
infection. b) Relationship between free platelets, plt:iRBCs and parasitaemia in infected mice 
Error bars represent SEM. ***p <0.001 2way ANOVA was carried out to determine 
differences in platelet binding. 
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4.3.5 Rate of Loss of Free Platelets vs Platelet Bound Red Blood Cells 
In order to determine the proportion of platelets bound to iRBC and uRBCs contributing to 
thrombocytopenia in infected mice, the total unbound platelets and biotinylated platelets 
were compared to platelet bound iRBCs and platelet bound uRBCs in Figure 4.12. The 
contribution complexes have in proportion to total platelets (platelet bound iRBCs + platelet 
bound uRBCs + biotinylated + nonbiotinylated platelets) was 2.5% on the day of 
biotinylation, 3.3% day one, 2.8% day two, 1.5% day three, and 1.1% on day four post 
biotinylation. However, again due to the inability to distinguish what part of the complex is 
biotinylated (the platelet or RBC) the concentration of complexes measured does not take 
into account newly formed complexes or platelets that may have become detached over the 
course of infection. The concentration of free biotinylated platelets decreases over the 
duration of infection whilst the total platelet pool also decreases, but takes into the account 
newly synthesized platelets. Taken together with data from the previous experiment, these 
results suggest that platelet complexes contribute a very small proportion of platelet loss in 
a mouse model of malaria-induced thrombocytopenia. 
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Figure 4.12 Preferential binding of platelets to infected and uninfected cells vs free 
platelets. Concentration total platelets (black), free biotinylated platelets (green), plt:iRBC 
(red) and plt:uRBC (blue) in infected mice (5) was measured via flow cytometry. Total 
platelets include plt:iRBC/plt:uRBC/biotinylated platelets and nonbiotinylated platelets. Red 
arrow indicates time taken for 50% of biotinylated platelets to remain in circulation. Error 
bars represent SEM. **p <0.01 
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Discussion 
It has been previously reported in a P. chabaudi mouse model of malaria, mice experience 
thrombocytopenia, with platelets preferentially binding to infected iRBCs rather than uRBCs 
[70]. The aim of this chapter was to determine if the thrombocytopenia that is observed in 
acute malaria may be a result of this platelet binding to RBCs and subsequent clearance of 
these platelet-RBC complexes.  
 
Reported platelet numbers in C57BL/6 mice are 1.0x109cells/mL [150]. These numbers 
correspond with the observed platelet concentrations in all three mouse experiments 
described in 4.1a, 4.3a and 4.8a. Various parameters such as sampling method and frequency 
of sampling could potentially cause platelet numbers to fluctuate, hence care was taken to 
avoid platelet activation during blood collection by using plastic pipette tips to decrease 
platelet activation. A small tail snip on a daily basis did not seem to cause platelet loss in 
uninfected mice as platelet concentrations remained stable throughout the course of the 
infection. However, as can be noted in Figures 4.1b, 4.3b and 4.8b there was a decrease in 
RBC numbers from the start of infection. For unknown reasons, RBC concentration was 
always lower in mice than the expected value, however control mice were sampled on the 
same schedule as their infected counterparts, and as such, they still serve as an appropriate 
control for platelet activation and RBC loss that could be caused by this sampling.  
 
There were statistically significant differences in platelet concentrations in infected mice 
compared to uninfected mice as parasitaemia increased, with peak parasitaemia coinciding 
with the lowest concentration of platelets. This occurred in all three P. chabaudi challenges 
(Figures 4.1a, 4.3a and 4.8a) which has previously been shown in a P. chabaudi model of 
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malaria [70]. This chapter demonstrates that, as reported in published work, 
thrombocytopenia occurs in mice with increasing parasitaemia and before clinical symptoms 
appear, such as anaemia. In previous studies in the McMorran lab, malaria challenges were 
carried out with cohorts of mice that were sacrificed each day [70]. Tracking the same mice 
over the course of infection, as in the current study, allows for fewer mice to be used and the 
measurement of platelet number in relation to parasitaemia, individually, limiting 
confounding factors. The concentrations of RBCs measured in this study were lower than 
published numbers (1x1010/mL) due to unidentified reasons. It is important to note that in all 
three challenges presented in this chapter, it appeared that daily bleeding from the mice may 
have resulted in a lower number of RBCs when compared to the post-infection RBC 
concentrations. The time taken for the bleeding to stop may further contribute to the loss of 
RBCs. 
 
During a malaria infection, the loss of platelets can either be attributed to platelet 
consumption or a decrease in platelet production. The first aim in this chapter was to measure 
clearance of platelets (or time it takes for 50% of the original biotinylated population to be 
consumed). Both Figures 4.4 (p 0.0357) and 4.9 (p 0.0159) show a significant decrease in 
platelet half-life in infected mice; this happens approximately 1.5 days in infected mice 
compared to 2.3 days in uninfected mice post-biotinylation. This increase in clearance 
suggests that during a malaria infection in mice, platelet consumption is higher than in 
uninfected mice. Figures 4.5 and 4.10 show between infected and uninfected mice on the 
same day, when the proportion of biotinylated platelets is compared, there was a significantly 
lower proportion of biotinylated platelets remaining during the infection. A difference in the 
concentration of non-biotinylated platelets suggests that the rate of consumption may have 
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exceeded the rate of production. This is shown by way of uninfected mice platelet 
concentrations staying in equilibrium, but infected mice platelet concentrations increasing 
more slowly. Taken together, platelet consumption plays a role but inhibition of platelet 
production may also be occurring. Future aims to measure the role of platelet production 
could include measuring megakaryocyte (platelet precursors) concentration in the bone 
marrow of mice over the course of infection, though this would mean having to sacrifice 
cohorts of mice daily.  
 
It has previously been shown that platelets bind preferentially to iRBCs compared to the 
proportion binding to uRBCs [70]. When calculating the proportion of platelet binding, it is 
important to consider two factors; 1) the concentration of platelets at a given time and 2) the 
proportion of iRBCs and uRBCs at the same given time. 
In all three experiments, the days which experienced preferential binding of platelets to 
iRBCs compared to uRBCs had both factors likely contribute to the positive result. It seems 
feasible that there is a significant difference in binding of platelets to infected cells than 
uninfected cells where there is a small population of infected cells in circulation but a high 
number of platelets, which is what occurs on the days which show preferential binding. 
Platelets may become activated on binding to RBCs which in turn could contribute to more 
platelets becoming activated and binding to uRBCs or iRBCs. 
 
To determine the effect platelet bound complexes had on thrombocytopenia, when the 
concentration of free biotinylated platelets and the total platelet pool was plotted against the 
concentration of platelet bound iRBCs and uRBCs (Figures 4.7 and 4.12), it was observed 
that over the course of infection, a very small percent of platelets were bound compared to 
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the total platelet pool. Platelet-bound- complex clearance is impossible to measure in the 
above experiments, due to the inability to distinguish which part of the complex is 
biotinylated (ie the RBC or the platelet, due to IV injection of biotin which labels all blood 
cells). This factor also makes it impossible to see the exact concentration of complexes being 
lost over time as it is impossible to determine when the complex was made. 
The concentration of complexes graphed in Figure 4.7 and 4.12 takes into account new 
complexes that are being formed thus making it difficult to directly compare free platelet loss 
with complex loss. However, what it does show is that the concentration of platelet 
complexes may only contribute to a small portion of malaria-induced thrombocytopenia as 
the proportion of platelets lost between days is greater than what complexes contribute. It is 
interesting to note that the concentration of platelets bound to iRBCs stays fairly constant 
across the duration of infection thus suggesting that platelets are either binding to iRBCs at 
the same rate they are detaching or not detaching at all and therefore not being cleared away. 
 
Future Directions: 
Future directions to further analyze the role of platelet binding could involve labeling 
platelets and RBCs ex vivo and injecting them back into the mouse, thus being able to 
distinguish clearly what part of the complex is biotinylated and hence the proportion of 
binding that is being lost over the course of infection. This in turn would allow the time taken 
for platelet complexes to be cleared from circulation and determine if they are being cleared 
away at a faster rate than free platelets which in turn could contribute to malaria-induced 
thrombocytopenia 
Organ sequestration studies could also be carried out by observing if plt:RBC complexes are 
sequestered in organs such as liver or spleen using in vivo live imaging technologies. 
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With platelets playing a potential protective role in malaria, mitigating platelet loss early on 
infection may help enhance the role of platelets in killing the malarial parasite.  
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Chapter 5 General Discussion 
The aim of this thesis was divided into two main parts; (i) discover molecules responsible 
for platelet activation when purified human platelets were incubated with P. falciparum with 
the subsequent release of PF4 and, (ii) observe thrombocytopenia in a mouse model of 
malaria using P. chabaudi and see the contribution platelets binding to red blood cells have 
in malaria-induced thrombocytopenia.  
 
It has been previously shown that platelets can bind to both iRBCs and uRBCs, but they 
release PF4 onto the surface of the iRBC only. Binding of iRBCs to platelets can occur via 
the platelet molecule CD36 and the iRBC ligand PfEMP1 but the molecule(s) unique to the 
iRBCs which allows subsequent PF4 release was to be determined (chapter 3). Using infected 
lysate via hypotonic lysis activation of platelets was inconsistent and incubation of platelets 
with trophozoite stages RBCs proved unsuccessful unlike previous studies. While previous 
studies have shown PF4 release [100, 111] but with different platelet:trophozoite ratios, no 
PF4 was released in the current study. It is possible that parasites were not viable from the 
time of purification to the time of use in the platelet assay, or that at a given point in 
trophozoite development, that parasites express or secrete certain platelet activating 
molecules which was not expressed at the time of the current studies parasite purification. 
Due to unsuccessful attempts at activating platelets, it was decided to move to the second 
aim of which focused on platelets in an in vivo setting and more specifically during malaria- 
induced thrombocytopenia (Chapter 4). 
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Thrombocytopenia is seen in various other parasites, bacterial and viral infections. In dengue 
virus infections for example, thrombocytopenia is observed in infected individuals and relies 
on two events; decreased platelet production in the bone marrow and/or increased destruction 
or clearance of platelets from peripheral blood [151]. In the early stages of dengue infection, 
studies have shown platelet activation (as determined by increased levels of anti-CD62P) and 
apoptosis (as shown by increased caspases and phosphotidylserine expression) [152, 153]. 
Activation of complement factor C3, followed by binding of C5b-9 complex to the platelet 
surface is also linked to thrombocytopenia in individuals [154, 155]. In malaria-induced 
thrombocytopenia, no exact mechanism has been elucidated although numerous mechanisms 
have been suggested, such as immune-mediated [156] and splenic sequestration [129] . The 
second part of this chapter was to observe thrombocytopenia in mice infected with P. 
chabaudi and to measure how much of platelet binding to RBCs contributed to 
thrombocytopenia.  
 
Platelets have been shown to preferentially bind to iRBCs over uRBCs and it is this binding 
that was hypothesised to contribute to thrombocytopenia through complex removal from the 
host's blood stream. Binding depends on two factors; the concentration of platelets at any 
given time and the percent of iRBCs. In all three infections in chapter four, there was a 
significant difference in binding to iRBCs compared to uRBCs the day before there was a 
significant difference in platelet concentration between infected and uninfected mice. This 
also coincided with when parasites were first observed in the bloodstream and may suggest 
that complexes are being cleared away. However, by comparing free total platelets over the 
course of infection to platelet bound iRBCs and uRBCs, it is seen that bound platelets 
contribute only a small percentage of total platelet concentration at a given time, although 
100 
 
without knowing the life-span of these platelets it is impossible to make this conclusion 
decisively. 
A number of methods have been described for platelet survival studies including isotopic 
labelling using 111In of 51Cr [157] whereas the duel isotopic labelling methods used in 
humans also allow the simultaneous measurement of survival for two platelet populations in 
animals. Nonisotopic labelling such as fluorescent platelet labelling allows the investigator 
to identify platelet populations using flow cytometry with biotinylation being the most 
popular. Although platelet specific markers could be used to study platelet survival such as 
X488, in the current study both RBC was to be measured alongside platelets. However, RBC 
biotinylation rates fluctuated over the days and was never consistent even in the initial days 
of biotinylation where % biotinylation should remain constant hence biotin over a platelet 
specific label was chosen.  
 
Biotinylation of platelets did however, show that platelet consumption occurs, and 
interestingly, that it is possible that platelet consumption exceeds platelet production. 
Biotinylation of platelets allows tracking of the original platelet population which was carried 
out in infections two and three of Chapter 4. It was observed that platelets in infected mice 
cleared platelets by approximately one day faster which suggests the role of platelet 
consumption in a mouse malaria model of thrombocytopenia. Direct comparison of 
biotinylated complexes and free biotinylated complexes was unable to be carried out due to 
the inability to distinguish what part of the complex is biotinylated. 
 
Overall, this thesis was unable to replicate the previous finding of platelet activation which 
was a prerequisite to finding the molecule(s) responsible for PF4 deposition onto the surface 
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of the iRBC and not uRBC. Platelets exposed to infected lysate of trophozoite stage parasites 
were able to be activated as based on anti-PAC1 expression but not consistently. 
Malaria induced thrombocytopenia was measured by developing a flow cytometry staining 
protocol allowing individual mice to be tracked over the course of infection. 
Platelet clearance was significantly faster in infected mice as determined by the percentage 
of biotinylated platelets remaining in circulation. A possible suppression of platelet 
production as indicated by a significant decrease of nonbiotinylated platelets in infected mice 
was also observed. 
Prior to the onset of thrombocytopenia, when platelet concentration was high and 
parasitaemia was quantifiable, there was preferential binding to iRBCs compared to uRBCs; 
however, due to inability to track platelet complexes over the course of infection and measure 
clearance, future evaluation  of clearance of platelet binding may provide more insight into 
the role they play towards malaria-induced thrombocytopenia. 
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